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Abstract
Glioblastoma (GBM) is an aggressive cancer which presents significant challenges
for disease management and treatment. Tissue sodium concentration (TSC) is a sensitive
indicator of disease and changes in TSC can be used as a potential biomarker for treatment
response. A longitudinal orthotopic C6 GBM model was used to study changes in TSC due
to cancer. Animals were imaged with contrast enhanced T1-weighted, T2-weighted and
sodium MRI and were either un-treated or received temozolomide (TMZ) treatment.
Accurate assessment of TSC was possible for tumour volumes greater than 150mm3 using
3mm isotropic imaging voxels. TSC increased with tumour growth for all animals.
However, no differences in TSC were observed between treated and non-treated animals.
This study demonstrates the feasibility of preclinical sodium MRI at 3T and highlights
future potential challenges to overcome for this modality.
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Summary for Lay Audience
Glioblastoma (GBM) is an aggressive brain cancer which presents significant
challenges for disease management and treatment. Tissue sodium concentration (TSC) is a
sensitive indicator of disease and observing changes in TSC can provide additional
information about tumour biology. Magnetic resonance imaging (MRI) is a powerful noninvasive imaging modality which uses the physics underlying magnetism to obtain images
of the body. MRI can capture the differences between soft tissues and provide detailed
structural and morphological information about internal areas of the body. Standard MRI
relies on the hydrogen atoms found in the body – particularly in the water to capture these
images. Sodium MRI applies the same principles used in standard MRI but instead on
sodium atoms found throughout the body, providing TSC information. In this study, C6
rats were implanted with GBM brain tumours and imaged longitudinally using standard
MRI techniques and sodium MRI. Animals were either untreated, or received treatment
using temozolomide (TMZ) – the chemotherapy drug used to treat GBM. Accurate
assessment of TSC was possible for tumour volumes greater than 150mm3 using 3mm
isotropic imaging voxels. TSC increased with tumour growth for all animals. However,
there were no differences in TSC changes between treated and non-treated animals.
Ultimately TSC at endpoint was lower for treated animals, however this difference was not
significant. This study demonstrates the feasibility of preclinical sodium MRI at 3T and
highlights future potential challenges to overcome for this modality.
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Chapter 1
1

General Introduction

1.1 Glioma
Out of all tumours arising in the brain and central nervous system (CNS), gliomas
are the most common [1]. In Canada, brain and CNS cancers are predicted to account for
7.1% of all diagnosed cancers for 2020 [2]. Glioma is a general term used to describe
tumours arising from glial cells and their precursors and include a variety of subtypes and
grades [3]. Between 2009 and 2013 in Canada, tumours arising from these tissues
accounted for over 80% of all diagnosed CNS tumours [4]. The World Health Organization
(WHO) has released new classification criteria for gliomas, reclassifying them as an
astrocytoma based on shared genetic markers. In this grading scheme, grades I and II are
considered low-grade tumours, while grades III and IV are considered high grade. Current
classification integrates both phenotypic and genotypic characteristics. In general, grade I
glioma is the least malignant and can be treated through surgical resection. Grade II glioma
is more infiltrative and more likely to recur and progress to higher grades. Grade III and
IV gliomas are highly infiltrative and aggressive, and associated with poor prognosis and
poor patient outcomes [5]. The following sections will expand on high grade gliomas and
the challenges associated with their treatment.

1.1.1 Glioblastoma multiforme
Glioblastoma (GBM) are grade IV gliomas, the most aggressive and infiltrative.
Cells from the main GBM tumour will migrate away from the main mass through the brain
parenchyma. This results in individual tumour cells diffusing through the brain tissue, over
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long distances, and potentially into vital regions of the brain. Since these diffuse cells can
extend beyond lesions visible by imaging, it becomes more difficult to have a full grasp on
the state of the disease. Furthermore, the location of GBM within the brain is often variable
and can occur in areas difficult to treat, further compounding aggressiveness of this disease
[6]. Additionally, GBM are also the most common malignant primary brain tumours,
accounting for 45.6% of all gliomas and 15.4% of all primary brain tumours [7]. The Brain
Tumour Registry of Canada reports that 12% to 15% of all intercranial tumours and 50%
to 60% of astrocytic tumours are GBM. Median survival for patients is merely 12 to 15
months after diagnosis and only 5% of patients survive to 5 years [8, 9]. GBM is
heterogeneous and multiforme on a macro and micro scale. Overall, GBM tumours display
regions of hemorrhage and necrosis, as well as regions of pleomorphic nuclei and cells,
and microvascular proliferation [6]. GBM can arise as a primary tumour – wherein the
cancer arises with no evidence of a precursor, or as a secondary tumour – developing from
a lower grade diffuse astrocytoma [10].

1.1.2 Glioblastoma therapy
The clinical standard for GBM treatment is maximal surgical resection, followed
by radiotherapy – 60Gy total split over 30 daily fractions of 2Gy each, concurrent with
chemotherapy using Temozolomide (TMZ) – administered for 7 days at a daily dose of
75mg/m2 [11].

However, despite this therapy, overall survival is still poor [8, 9].

Unfortunately, the median time to tumour recurrence is 8 months [5]. This rapid recurrence
is likely because treatments cannot eliminate all the tumour cells [8]. Maximal surgical
resection is limited by the diffuse nature of the disease; making it difficult to distinguish
the cancerous tissue from healthy tissue [8]. It can additionally be limited by the tumour’s
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location in or near vital brain regions, and the rapid growth of the residual cancer stem cells
after surgery [5, 6]. Radiotherapy is also limited by the diffuse nature of the disease, as
targeted radiotherapy cannot hope to affect individual cells which have spread from the
primary tumour. Chemotherapy effectiveness is limited by the blood brain barrier (BBB),
restricting drug penetration into brain cells, and the heterogeneity of the cells, resulting in
variable effectiveness [5, 8]. Upon GBM recurrence, treatment faces additional challenges.
Surgery may not be possible after recurrence. Additionally, chemo- and radiotherapy
options are limited at that point. In addition to no standard for second line chemotherapy
in GBM treatment, the recurred tumour can acquire a chemo-resistant phenotype [1, 8].
Re-irradiation carries with it a risk of toxicity, as well as brain necrosis or radiation-induced
injury [3, 8].

1.2 Sodium and metabolism in biological tissues
Sodium is the most abundant cation in the body and plays a key role in many
cellular processes, such as nerve conduction, muscle contraction, and maintaining tissue
osmolarity [12, 13]. Changes in sodium distribution within cells and tissues is associated
with many pathologies. Sodium concentration (mol/L = M) is maintained at 10-15mM
intracellularly and 140mM extracellular in healthy tissue [14]. This section provides
background information about the role sodium plays in healthy tissues and the changes that
occur in a cancerous phenotype. Changes in pathways regulating sodium form the basis for
a heterogeneous sodium distribution that is characteristic of disease.
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1.2.1 Tumour metabolism
Sodium concentrations in the intracellular and extracellular space are carefully
maintained for regulating proper cell function and volume [12]. The large sodium
concentration gradient is maintained by a variety of active transport, voltage, and ligand
gated channels. The most prominent transporter involved is the Na+/K+-ATPase or the
sodium-potassium pump. This plasma membrane protein is expressed in most eukaryotic
cells, and functions to maintain the sodium and potassium gradients. By using the energy
from hydrolyzing adenosine 5’-triphosphate (ATP), the Na+/K+-ATPase transports three
sodium ions out of the cell while pumping two potassium ions in, this enables healthy cells
to maintain their low intracellular sodium levels [13]. Impairment of Na+/K+-ATPase
function or cell membrane integrity can lead to an increase of intracellular sodium. Another
important transported involved in sodium transport is the Na+/H+ antiport (NHE) or the
sodium hydrogen antiporter. This membrane protein exchanges one intracellular hydrogen
ion for one extracellular sodium. Of the NHEs, isoform I (NHE1) is expressed in most
tissues and cells. NHE1 functions to maintain cytosolic pH as well as cellular volume [15].
The significance of sodium exchange acting to maintain intracellular pH is key to the
Warburg effect that will be further discussed in section 1.2.2 and 1.2.3.

1.2.2 Sodium ion flux in cells
Healthy cells in a multicellular organism participate in controlled growth by heavily
regulating their metabolic pathways. This is required as these cells receive a constant
supply of nutrients. Control of metabolic activity prevents aberrant cell proliferation that
exceeds nutrient availability. Healthy cells in aerobic conditions produce energy in the
form of ATP through the heavily regulated pathway of oxidative phosphorylation in the
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mitochondria [16]. Lactate is only produced in in anaerobic conditions. Cellular
metabolism is altered in cancers, as cell survival and growth are promoted by
circumventing oxidative phosphorylation to produce ATP through glycolysis even in
aerobic conditions. The Warburg effect describes the tendency of cancer cells to ferment
glucose to lactate regardless of oxygenation conditions, resulting in cancer cells
undergoing aerobic glycolysis [17]. Aerobic glycolysis is much less efficient than oxidative
phosphorylation in the production of ATP, however this process is virtually unregulated
and in addition promotes tumour growth and proliferation. Tumours are effective in
deriving the additional biomass needed for growth and proliferation from glycolysis
because of the inefficiency of this pathway. Glycolysis produces numerous side products
while metabolising glucose compared to oxidative phosphorylation uses all the available
carbons in glucose to produce ATP [16]. This excessive production of lactate via aerobic
glycolysis has implications for cellular health and homeostasis as lactate is transported out
of the cells and used as biomass to further tumour growth [16].

1.2.3 Sodium in cancer
Excess production of lactate by aerobic glycolysis enables several malignant
characteristics of cancerous cells. Due to the increase in proton concentration within the
cell, intercellular conditions become acidic. To maintain cellular function, excess protons
must be expelled from the cell. This results in extracellular acidosis as the protons begin
accumulating outside of the cell. A heterogenous distribution of acidity, hypoxic
conditions, and other environmental factors create the conditions to produce a highly
heterogeneous tumour population that is malignant. The increase in proton concentration
outside the cell has additional consequences. Various proton transport proteins are heavily
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involved in the extrusion process, with the most prominent being the sodium proton
antiporter (NHE1), a transporter upregulated in GBM [18]. This protein can be upregulated
up to 15-fold over the expression level in human neural stem cells [19]. This channel
exchanges protons for sodium ions on a one-to-one ratio. Over time, this action contributes
to the increase in sodium concentration within the cell due to the accumulating sodium
ions.
Additionally, sodium concentration in the tumorous region can be affected by
changes in the ratio between the intracellular and extracellular volume fractions. The
extracellular volume fraction occupies a much smaller area than the intracellular space, but
has a much higher sodium concentration [20, 21]. Increases in the extracellular volume
fraction due to increased perfusion in the region, increased leaky vessels, or remodeling of
the tumour micro-environment due to cancerous growth can cause overall tissue sodium
concentration to also increase [21]. Overall, sodium concentration has shown to be
increased in tumours and has potential to act as a biomarker for tumour growth [18, 22,
23].

1.3 Pre-clinical GBM animal models
Preclinical models are essential for the translation of research as they link the
translation of in vitro cell based researched into clinical application and in vivo studies.
These models allow researchers to test the applicability and translatability of their findings
within a more complex system for the eventual hope of application into clinic or human
settings. Preclinical models also find applicability in the testing of novel imaging
modalities such as magnetic particle imaging (MPI) [24]. Evaluating and validating these
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new imaging modalities in preclinical models of disease lays the foundation for assessing
the relevance of these new modalities for human imaging.
Translatable imaging methods require animal models which can accurately
recapitulate the biological interactions and clinical progression of human disease.
Depending on the topic of study, different models will reproduce different aspects of the
target biology. For preclinical GBM models of human gliomas the following features are
desired: an approximating genotype, similar genetic, epigenetic, and phenotypic intratumoral heterogeneity, and the development of a representative tumour micro-environment
(including immune cell interactions, cell-cell interactions, and BBB) [25].
Animal models for the study of GBM have been developed for in vivo studies. The
most common models used are small rodents, having multiple strains and species
applicable to different purposes. Small rodent models can be generated in several ways,
although cell-line derived models are the most common. Cell line-derived models rely on
cancer inoculation using established, long-term in vitro cultured tumour cells. These cell
lines can be transplanted into syngeneic hosts for allographic or xenographic (humanbased) models. In addition, cell-line cancer cells can be placed either ectopically, or
orthotopically in its natural tissue of origin. Preference of model, cell-line type, and
location depends on which aspect of cancer biology is of interest [26]. For example, the
U87 glioma is a human derived GBM cell line which has been used extensively for
investigating tumour angiogenesis and anti-angiogenic therapies. However, this cell line
fails to replicate key GBM phenotypes, such as diffuse infiltration, and a homogeneous
appearance when imaged. Comparatively, the U251 glioma is also human derived, but
better recapitulates the phenotypic aspects of GBM where U87 fails [27]. Having a cell
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line which can capture the genotypic and phenotypic characteristics of GBM improves the
translatability of research which relies on these cell lines. Ideally, research would be
conducted using patient-derived xenographs which could capture the complexities and
nuances of GBM [28].
Of the available small rodent pre-clinical models, mouse models are most
commonly used due to their ubiquitous use for genetic manipulation, having been used to
generate a variety of immunocompromised strains which have been used with many celllines [29-31]. However, there are two major considerations with these models. The first
applies only to immunocompromised models using human cells, where the characterization
of biological behaviour may be impacted due to the lack of tumour-immune cell
interactions. Implantation in immunocompetent models allows for the study of tumour
immunological characteristics, whilst implanting in immunocompromised animals allows
for the evaluation of immunotherapies [32]. The second limitation is due to their small size,
which limits their use for certain imaging applications as the spatial resolution needed for
effective imaging could impact the signal-to-noise ratio (SNR) of the modality. With
magnetic resonance imaging (MRI), this limitation can be overcome using high magnetic
field strengths or using custom coils and gradient hardware [27].
Pre-clinical rat models are likewise a useful tool available for cancer models.
Although most of these models are allogenic cell-line based due to the difficulty of
producing immunocompromised strains. The major advantages of working with rat models
include the greater accuracy for tumour implantation, as well as greater physiological
similarities to humans, as compared to mice [32]. Several GBM cell-line models have been
developed in different rat species, with the most used lines being C6, 9L, and F98 cell-
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lines. The 9L gliosarcoma cell line has been the most widely used experimental rat brain
tumour model, and has been used extensively to study chemotherapy and radiation therapy
[27, 32]. However, considerations must be taken when using gliosarcoma as a model for
GBM, as there are distinctions between the behaviour of these diseases [27, 33]. The F98
glioma cell line is more representative comparatively, replicating human glioma invasive
growth patterns and gene expressions, however F98 tumours resemble anaplastic gliomas
more than GBM tumours [27, 34]. Of similar comparability is the C6 glioma cell line,
which will be further described in the next section.

1.3.1 C6 rat GBM models
The C6 rat GBM cell-line was developed in the late 1960s in Sweet’s laboratory in
adult Wistar-Furth rats though repeated administration of N-methylnitrosourea [27, 32].
This cell-line has been shown to have several histopathological similarities to human GBM.
The cells are spindle shaped and pleomorphic with variably shaped nuclei, resembling
human GBM cells [34]. Tumours generated from C6 cells in Wistar rats have been shown
to have moderate foci of necrosis, with regions of focal invasion, nuclear polymorphism,
and a high mitotic index [27, 34].
The C6 cell-line has several genetic similarities to human gliomas as well,
demonstrating similar changes in gene expression to human brain tumours. For example,
both C6 and human GBM show frequent mutations in p16 – a common tumour suppressor
heavily implicated to play a role in primary brain tumour development [27, 35].
Specifically, C6 cells have been reported to have a mutated p16/Ckn2a/Ink4a locus, with
no expression of p16 and p19 adenosine diphosphate (ADP) ribosylation factor (ARF)
mRNAs [36]. Some notable differences between human-gliomas and the C6 cell line
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include the wild type p53 that C6 cells possess [27]. Additionally, C6 cells have lack of
glial fibrillary acidic protein – a common diagnostic marker for GBM in humans [37], and
variable expression of vimentin – a cytoskeleton protein that has been associated with
metastatic disease and the progression of GBM [38].
Typically, C6 cells can be implanted and grown in Wistar rats, but they have been
implanted in the Sprague-Dawley and Long-Evans strain without rejection [27]. However,
it should be noted that C6 tumour growth in Sprague-Dawley and Long-Evans differs
greatly from growth in Wistar rats, approximating brain metastasis growth behaviour with
reduced infiltration and without parenchymal invasion. When implanted inside the Wistar
rat, the growth pattern of C6 more closely resembles its human counterpart. In addition,
the immune micro-environment of the C6 tumour resembles human GBM [34]. It is
important to note there exists a level of immunogenicity in response to the tumours within
Wistar rats, such that C6 cells cannot be used for assessing immunotherapies [27]. Despite
this, C6 tumours are extremely well studied and have been used to study tumour growth,
cell invasion and migration, tumour angiogenesis and BBB disruption. In addition to
mirroring the biology, C6 cells also mirror imaging characteristics of human gliomas –
making it especially useful in imaging studies [34].

1.4 Clinical imaging of GBM
Monitoring and assessing tumour progress is very important in GBM disease
management and treatment. Non-invasive imaging methods for evaluating disease
progression and treatment response form the basis for decisions to alter or abandon the
current therapy regime for salvage therapy [39].

These methods largely consist of
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anatomical imaging modalities such as 1H MRI, x-ray computed tomography (CT), or
positron emission tomography (PET).
These modalities are used to provide insight into brain anatomy, structural
abnormalities, tumour location and degree of spread, and in some cases, functionality. The
current standard for brain tumour imaging is MRI, either with or without contrast
enhancement, or CT if the patient is unable to undergo MR imaging (due to a pacemaker
or other magnet sensitive implants) [40]. If available, PET has been recommended and
used as an additional clinical diagnostic assessment tool evaluating functional
characteristics of the tumour, with glucose metabolism tracers and amino acid transport
tracers being used predominantly [41].
The following section describes the use of MRI for monitoring GBM in greater
detail, as well as examining the advantages and challenges associated with the modality.

1.4.1 Magnetic resonance imaging
There are a variety of MRI sequences available for anatomical imaging. Two- (2D)
or three-dimensional (3D) imaging data sets can be acquired with different endogenous
contrasts depending on the parameters selected. Typically, T1-weighted, T2-weighted and
contrast enhanced (CE) sequences are used to evaluate GBM as the presence of the tumour
influences the image contrast by modifying the underlying tissue structure [42]. Imaging
with MR provides the most value in early disease detection and guiding intervention. The
gold standard for diagnosing and monitoring GBM is brain MRI. Typically, gadolinium
(Gd) CE MRI is used, as glioma lesions tend to show contrast enhancement in T1-weighted
post-Gd images [43]. MR-based evaluations can provide high resolution and high contrast
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anatomical images with high sensitivity but limited specificity [43]. Serial imaging with
MR has revealed several prognostic features which have been associated with patient
survival outcomes, such as edema – associated with poor prognosis, and non-contrast
enhancing tumour – associated with longer survival [42, 43]. Additionally, research into
advanced MR sequences have been able to discern various features characteristic of GBM.
Techniques such as diffusion weighted imaging, dynamic susceptibly contrast enhanced
perfusion imaging, and MR spectroscopy have been used in research to study GBM
progression and treatment response [44-46].
Given the current gold standard of GBM monitoring and diagnosis, several major
challenges exist. Firstly, there are numerous non-neoplastic conditions which can mimic
gliomas on neuro imaging such as: brain abscesses, subacute stroke, or other inflammatory
diseases. In many cases, these conditions may also mimic similar symptoms. Therefore it
is essential to not solely rely on brain MR for GBM diagnoses [40]. Monitoring treatment
effect on GBM using MR presents additional challenges. Pseudo-progression and pseudoresponse are the major confounding factors in GBM monitoring. Pseudo-progression is
what appears as an increase in contrast enhancement and/or edema without true tumour
progression. The appearance of pseudo-progression is most commonly associated with MR
imaging after treatment with concomitant radio- and chemotherapy with TMZ followed by
disease stability or lack of clinical progression [43]. Pseudo-response is what appears as a
decrease in enhancement without true anti-tumour effect and is generally associated with
anti-angiogenic therapies [43]. This occurs due to reduced delivery and retention of the
contrast enhancement agent in cancerous region, resulting in a decrease in contrast
enhancement. It is imperative to accurately differentiate recurrent or progressive tumours
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from imaging artefacts and differential treatment response. Failing to identify these
pseudo-phenomena can lead to premature termination of effective therapies, unnecessary
surgical interventions, or the use of additional treatment agents [3]. Unfortunately, pseudoprogression is a relatively common phenomenon and has been observed in up to 50% of
all patients with GBM in their first post-therapy MR scan 2-3 months following chemoradiotherapy [47, 48]. Pseudo-progression can be induced by a variety of causes related to
the treatment itself including inflammation, ischemia, and radiation-induced necrosis [3,
49]. Radiation necrosis can appear as a single “lesion” at the resection site which can appear
as a recurrent tumour. In areas far from the primary tumour, necrosis can mimic multifocal
lesions [49]. As this pseudo-phenomenon often presents after treatment, this limits the
application of CE MRI for post-surgery evaluation, as the pooling of fluids or vascular
damage results in CE that does not reflect the true disease state. Discriminating between
pseudo-progression and true progression is difficult since conventional MR cannot
differentiate the two. Additionally, pseudo-progression can resolve spontaneously, which
can mislead observers to believe that the treatment is effective [50]. This spontaneous
resolution is likely due to healing of the BBB and clearing of edema from the area which
reduces CE in the region [51]. Identification of pseudo-progression is imperative as
diagnosis can influence the choice to either continue with adjuvant therapy or change to a
second-line therapy [39, 52]. While MRI continues to be the most accessible and powerful
modality for evaluating tumour progression, such limitations necessitate development by
future research.
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1.4.2 The Macdonald criteria
The current most widely used guideline for evaluation of response to therapy in
high grade gliomas is the Macdonald criteria [52]. The Macdonald criteria was established
in the 1990s and has been widely adopted since [42]. Evaluation of glioma by the
Macdonald criteria relies predominantly on 2D anatomical tumour measurements from
consecutive post-Gd T1-weighted MRI scans concurrent with clinical assessment and
corticosteroid dosing [52, 53]. This allows for evaluation of neurological symptoms and
the use of corticosteroids to target tumour-induced edema [54].
According to the Macdonald criteria, high grade glioma tumours are assessed based
on changes in the largest cross-sectional area from consecutive post-Gd T1-weighted
images obtained at least 1 month apart [53]. The cross-sectional area measurement is
obtained from the product of the largest cross-sectional diameter and the largest diameter
perpendicular to it. Tumour response is classified into one of four categories: complete
response (CR), partial response (PR), progressive disease (PD), and stable disease (SD).
The imaging evaluation criteria for CR is the complete disappearance of enhancing disease
on consecutive MRI scans at least one month apart. A classification of PR requires a greater
than 50% reduction in the size of the enhancing tumour on consecutive MRI scans and no
new lesions. A classification of PD requires a greater than 25% increase in the enhancing
tumour size, or the appearance of new lesions. Lastly, SD consists of scenarios which do
not fall into any of the above [53].
The widespread adoption of the Macdonald criteria and the advent in imaging
technology and therapeutics has revealed many areas where the current measures lack
specificity and sensitivity for assessing response to therapy. Specifically, the criteria have
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been criticized for its ambiguity for defining appropriate thresholds for lesion size and lack
of detail in how to apply the criteria [42]. Critically, the scope of the Macdonald criteria
does not address the challenges of pseudo-progression and pseudo-response. This is largely
due to how heavily the criteria relies on Gd-enhanced images. It is also important to note
the limitations inherent in the tumour measurement technique, where the maximal
perpendicular diameters in the contrast enhanced tumour are used to calculate a crosssectional area. This measurement method has limitation application in irregularly shaped
tumours and can be subject to inter-observer variability [55].
Contrast enhancement in tissues relies heavily on vascular permeability. This can
severely limit its applicability in non-vascularized tumours and when used in conjunction
with anti-angiogenic drugs [56]. Additionally, contrast enhancement for glioma in posttreatment brain is non-specific and cannot be considered a true measurement of tumour
response but rather the integrity of the BBB [52]. Enhancement can also be confounded by
a variety of factors, including radiation necrosis, inflammatory response, edema in the
surrounding tissues, changes in corticosteroid doses, and radiological technique. This
makes changes in contrast enhancement subject to many factors and thus limits
interpretation as changes in enhancing area cannot be directly equated to changes in tumour
size [55].

1.4.3 Response Assessment in Neuro-Oncology
The Response Assessment in Neuro-Oncology (RANO) criteria was introduced in
2010 to address the limitations of the Macdonald Criteria [50]. While the criteria are
currently largely used for clinical trials, it is the current gold standard for evaluation of
pseudo-progression and improves on the Macdonald Criteria significantly. The RANO
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criteria introduced assessment for non-enhancing areas of the tumour and critically focused
on identifying pseudo-progression [39]. The RANO criteria utilizes T2-weighted and fluidattenuated inversion recovery (FLAIR) imaging in addition to Gd-enhanced MR images as
part of the imaging criterion for response assessment. The usage of T2-weighted and FLAIR
imaging produce tumour contrast without the use of agents and allow for identification of
changes in non-enhancing areas [55].
Like the Macdonald criteria, the RANO criteria also uses the cross-sectional area
produced by the maximal perpendicular diameters in the contrast enhancing area [55]. For
measurable disease, the diameters must be obtained from CT or MR scans with clearly
defined margins. Diameters must be at least 10mm and visible on two or more axial slices
at most 5mm apart. Disease is considered unmeasurable when lesions do not have clearly
defined boundaries and diameters less than 10mm. Unlike the Macdonald criteria, RANO
also introduces measures for multifocal lesions – where at least the two largest lesions
should be measured. In cases of high grade gliomas a maximum of five of the largest
lesions should be measured [55, 56].
The RANO criteria also divides tumour response into CR, PR, PD, and SD criteria.
Where basic imaging criterion for CR is defined as no enhancing disease for 4 weeks and
stable or improved T2-weighted/FLAIR visible lesions; indicated by minimal changes or
reduced lesion size. Criteria for PR requires ≥ 50% decrease in enhancing lesion size with
stable or improved T2-weighted/FLAIR lesions and no appearance of new lesions. Criteria
for PD requires a ≥ 25% increase in enhancing lesion size, increased T2/FLAIR lesion size
and/or appearance of any new lesions outside the radiation field [39]. There are also
additional criteria for the identification of pseudo-progression [50]. Under RANO, true
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tumour progression within the first 12-weeks post-radiotherapy occurs if most of the new
enhancement occurs outside the radiation field or with histological confirmation [3, 42].
However, practices for evaluating progression within the radiotherapy field requires MR
changes to persist for at least 4 weeks before being definitively confirmed [3].
Despite the improvements RANO has made to previous criteria, limitations still
exist. Although non-enhancing regions are taken into consideration using T2-weighted and
FLAIR imaging, changes in the non-enhancing regions can occur due to treatment, surgery,
or radiotherapy [42]. The addition of non-contrast enhanced criteria is limited by the lack
of objective imaging parameters resulting in subject interpretations and high adjudication
rates [3, 56]. RANO is still limited as it still uses bidirectional measurements of contrast
enhanced tumour size. This method of measurement has been shown to overestimate
tumour volume and results in higher reader discordance due to the challenges of identifying
the longest perpendicular diameters in irregularly shaped tumours [56]. Additional
limitations are presented in the arbitrary thresholds for defining response and progression
– as the use of thresholds based on percentage change from baseline are biased towards
small tumours as small changes in absolute tumour size result in large percentage changes
[56].
Currently, RANO still remains the gold standard for assessing tumour response in
GBM. Although limited in several aspects, it improves significantly upon the previous
Macdonald criteria and introduced new criteria for addressing pseudo-progression and noncontrast enhancing lesions.
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1.5 Basics of magnetic resonance imaging
Magnetic resonance imaging (MRI) is a versatile modality used for medical
imaging. It provides superior contrast between soft tissues compared to other modalities
such as CT or ultrasound (US). MR imaging can produce 2D and 3D images with
differential contrasts. This allows for identification of abnormalities or diseases that may
appear differently under different imaging conditions.
Standard MRI uses a strong, homogeneous magnetic field to induce nuclear
magnetization in hydrogen atoms associated with water molecules and fat in the subject.
The magnetic field is generated by a superconducting magnet which can be used to generate
magnetic fields on the order of Teslas (T). Comparatively, a fridge magnet averages around
1mT. Fields strength is often associated with specific imaging applications. Scanners used
in clinical settings can range between 1.5T to 3T. Scanners used for research purposes can
have field strengths ranging up to 21.1T [57]. However, most commonly these high-field
research scanners will range from 7T to 10T [58].
This section will provide a general overview of the physics governing magnetic
resonance image formation and factors affecting image contrast.

1.5.1 Nuclear spin and magnetization
The foundation of MRI relies on nuclear magnetic resonance of a nucleus of
interest. Traditionally, the proton is the nucleus of choice due to its high in vivo
concentration (80M) and high MR sensitivity due to its magnetic dipole moment [59].
Nuclei that can undergo magnetic resonance must have a non-zero spin and hence, a
magnetic dipole. The magnetic dipole can be conceptualized as a free precessing bar
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magnet in space. Typically, these magnetic dipoles are randomly oriented, resulting in a
net-zero magnetization as the magnetization cancels over the volume for a large ensemble.
⃑⃑⃑⃑0) – such as the field
However, in the presence of a large external magnetic field (𝐵
generated by an MRI, the magnetic dipoles precess around ⃑⃑⃑⃑
𝐵0 . The distribution of angles
in the cone of precession is almost uniformly distributed between 0° and 180°, with a slight
preference for smaller angles with increasing field strength. This results in a net
⃑⃑⃑⃑⃑0 ) which underlies the source of the MR signal (Figure 1-1.) [60].
magnetization (𝑀

Figure 1-1. Illustrative schematic showing orientation of magnetic dipoles in the

⃑⃑⃑⃑0 ). Magnetic dipoles preferentially align
presence of a large external magnetic field (𝐵
⃑⃑⃑⃑⃑0 ).
in the direction of the large magnetic field resulting in a net magnetization (𝑀
By convention, the direction of ⃑⃑⃑⃑
𝐵0 is used to define the Z-axis of a Cartesian
coordinate system. The rate of precession of the protons for a given ⃑⃑⃑⃑
𝐵0 depends on the
nucleus of interest and the strength of B0 and is described by the Larmor frequency (𝜔0 )
as defined by equation 1.1 [59].
𝜔0 = 𝛾̅ 𝐵0

(1.1)
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Where 𝛾̅ is the gyromagnetic ratio; an intrinsic characteristic of MR sensitive nuclei
which describes the magnetic dipole strength. The gyromagnetic ratio for some common
nuclei is listed below in Table 1-1.

Table 1-1. Gyromagnetic ratios (𝛾̅ ) of some commonly imaged nuclei. Of these, 1H is
the most imaged nucleus, with the largest 𝛾̅ ) value.
The ⃑⃑⃑⃑⃑
𝑀0 of a volume can be affected by several factors. Including the number of
magnetic nuclei per unit volume, the magnetic moment of these nuclei (as described by 𝛾̅ ),
and ⃑⃑⃑⃑
𝐵0. MRI is practically limited by the sample magnetization which limits the speed of
image acquisition and achievable image resolution. Imaging of hydrogen protons is
ultimately made feasible by the combination of these factors as the concentration of protons
in soft tissue is approximately 80M and 62% of all nuclei in the body are protons [59].
Moreover, imaging of non-hydrogen nuclei (X-nuclei) must overcome these challenges to
present with useful MR signals. These challenges will be detailed further in section 1.6.
To detect MR signal, ⃑⃑⃑⃑⃑
𝑀0 must first be rotated away from its position along the Z⃑⃑⃑⃑1) generated by a transient
axis through the action of a second oscillating magnetic field (𝐵
radiofrequency (RF) pulse. This field oscillates at the Larmor frequency in the XY plane
perpendicular to the Z-axis. The B1 field excites or “tilts” ⃑⃑⃑⃑⃑
𝑀0 away from the Z-axis to some
desired angle, after which is it turned off. The angle that ⃑⃑⃑⃑⃑
𝑀0 is tilted is known colloquially
as the flip angle (𝛼). For example, for an 𝛼 of 90°, ⃑⃑⃑⃑⃑
𝑀0 would rest completely in the XY
plane. Following the transient RF excitation ⃑⃑⃑⃑⃑
𝑀0 will begin to relax or “decay” back to its
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original position along the Z-axis. The amplitude of the magnetizations’ projected
components over time characterize different relaxation profiles. The amplitude of the
magnetization in the XY-plane decays from a maximum to a minimum, while the
amplitude of the magnetization along the Z direction recovers back to its original value.
The decay of the magnetization in the XY plane and the regrowth of the magnetization
along the Z-axis are known as the transverse and longitudinal relaxations respectively.
Contrasts between tissues in MR relies on the differences in relaxation profiles from
different tissues [59]. These concepts of relaxation, contrast, and signal detection will be
further expanded upon in following sections.

A

B

⃑⃑⃑⃑⃑0 )
Figure 1-2. Illustrative schematic showing the behaviour of the net magnetization (𝑀
⃑⃑⃑⃑0 ). Grey arrows show the direction of
under (A) excitation by an external field (𝐵
movement of the ⃑⃑⃑⃑
𝐵1 and ⃑⃑⃑⃑⃑
𝑀0 . (B) Shows the behaviour of ⃑⃑⃑⃑⃑
𝑀0 after being tilted away

⃑⃑⃑⃑0 ). Dotted lines show the longitudinal and transverse
from the main magnetic field (𝐵
magnetization components of ⃑⃑⃑⃑⃑
𝑀0 and 𝛼 shows the flip angle of ⃑⃑⃑⃑⃑
𝑀0 .
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1.5.2 Transverse magnetization and relaxation
The transverse magnetization is the component of ⃑⃑⃑⃑⃑
𝑀0 projected into the XY plane.
This magnetization holds its largest amplitude immediately after all the magnetization has
been flipped into the transverse plane after an 𝛼 of 90°. Over time, this component will
decay to zero as ⃑⃑⃑⃑⃑
𝑀0 precesses around ⃑⃑⃑⃑
𝐵0. This decay is exponential with time, t and is
described by equation 1.2

𝑀𝑡 = 𝑀𝑡 (0)𝑒

−

𝑡
𝑇2

(1.2)

Where T2 is the transverse relaxation time constant, an intrinsic characteristic of the
material being imaged. In vivo, T2 values are tissue specific and can differ based on tissue
type and composition [59, 61].
Transverse relaxation (also known as spin-spin relaxation) occurs due to a
dephasing of the precessional phases of individual constituent magnetic dipoles in the
tissue. This reduces the net amplitude of the transverse magnetization. Dephasing occurs
more rapidly in a non-uniform magnetic field as different field strengths occurring across
an imaging voxel will result in different local precessional frequencies. The T2*, also known
as the effective T2 accounts for this field inhomogeneity and is also affected by other
external factors such as system imperfections, tissue/air (or tissue/metal) interfaces, and
blood oxygen levels. This effective T2 is always shorter than the intrinsic T2 value of tissue
[59]. The impact of T2* can be overcome through MR sequence design, particularly by
using the spin echo sequence which will be further described in section 1.5.6.
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1.5.3 Longitudinal magnetization and relaxation
The longitudinal magnetization is the component of ⃑⃑⃑⃑⃑
𝑀0 along the Z-axis. Overtime,
this component exponentially grows from a minimum back to the original ⃑⃑⃑⃑⃑
𝑀0 value. This
growth can be characterized by the following equation [61].

𝑀𝑧 (𝑡) = 𝑀0 (1 − 𝑒

−

𝑡
𝑇1 )

(1.3)

Here T1 is the longitudinal relaxation (also known as the spin-lattice relaxation) time
constant, or the characteristic time taken for the magnetization vector to realign with the
direction of B0. When ⃑⃑⃑⃑⃑
𝑀0 has been tilted to 90o, the longitudinal magnetization component
is zero, but begins to grow back through longitudinal relaxation. Like transverse relaxation,
longitudinal relaxation rates differ depending on the tissue. By convention, the T1 value of
a specific tissue is defined as the time taken for the longitudinal relaxation to reach 63% of
its final value assuming a 90o pulse is used [59].

1.5.3.1 T1 contrast agents
T1 contrast agents find their use in MR imaging by increasing the specificity of MR
contrast. These agents have magnetic properties which manipulate the T1 of tissue in their
vicinity and increases the differences in signal between tissues at specific T1 times. Contrast
enhancement occurs due to shortening of the targeted tissue’s T1 values. This increases the
signal of the target tissue while the background signal remains the same when imaged with
a MR sequence with T1 contrast weighting. Enhanced relaxation occurs due to strong dipole
interactions between the proton magnetic dipole moment and that of unpaired electrons in
the contrast agent. Contrast agents with unpaired electrons are paramagnetic and are
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typically lanthanide compounds (such as gadolinium) which require chelation due to
concerns over metal toxicity. The chelation allows the hydrogen protons in water molecules
to get close to the paramagnetic agent for dipole-dipole interactions but prevents absorption
of the toxic agent within the body. Gd-based contrast agents are typically delivered through
an IV bolus with arterial enhancement lasting for a few minutes. Generally, the contrast is
non-specific and could depend on the vascular perfusion in the region of interest [58, 62].

Figure 1-3. Pre (L) and post (R) gadolinium contrast enhanced images of the rat head
from a coronal view. Enhancement can clearly be seen in the region of the tumour and
in the region surrounding the eyeballs.

1.5.4 T1 and T2 weighted imaging
The intrinsic differences among T1 or T2 values in different tissues underlies the
ability of MRI to distinguish soft tissues. Sequence design for MR imaging takes advantage
of these differences to produce images with different contrasts. The typical MRI sequence
consists of a series of RF pulses repeated over time, known as a pulse sequence. In a
standard pulse sequence, there is a specified period between RF excitation and when signal
acquisition begins. This time is known as time-to-echo, or TE. This gives the tilted ⃑⃑⃑⃑⃑
𝑀0 a
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period to relax. As mentioned above, this relaxation occurs at different rates for different
tissues in vivo. Ideally, when signal acquisition begins, the differences between the
magnetization of different tissues are maximized, generating contrast between them.
Optimal choices for TE depend on the contrast weighting of the image, and the area being
imaged. An additional factor to consider is the time between each pulse sequence
repetition, known as the time-to-repeat or TR. This is the time between each excitatory RF
pulse. Adjusting this time allows for the magnetization to relax to a desired state before
repeating the pulse sequence. Variation of TE and TR provide the basic methods to adjust
image contrast. T1-weighted images can be obtained using pulse sequences with short TEs
and short TRs. Under this contrast, fluids will typically appear darker while fattier tissues
will appear brighter. T2-weighted images can be obtained with long TEs and long TRs.
Under this contrast, fluids will typically appear brighter and fats tissue will appear darker
[59].

1.5.5 Spin-density weighted imaging
A less commonly imaged MR weighting is spin-density weighted imaging, also
known as proton density or nuclear density weighted imaging. In this weighting, the
contrast between tissues relies solely on the number of magnetically resonant nuclei within
the volume and tissue of interest. This produces contrast that is proportional to the
concentration of nuclei. With brighter areas having more MR sensitive nuclei than darker
areas. These images can be obtained using pulse sequences with long TRs and short TEs.
The long TR allows the T1 of the tissue to recover to the original value, removing T1 effects.
The short TE minimizes T2 effects as decay is minimized [59, 62]. In X-nuclear imaging,
this spin-density weighting can be achieved by modifying sequences to have TRs and TEs
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that reflect the T1 and T2 values of those nuclei in tissues. This provides a method to
interrogate the concentration of the X-nucleus within the volume of interest. This type of
X-nuclei imaging has been used to investigate 19F and 23Na in vivo as molecular imaging
probes [13, 63].

1.5.6 Spin echo imaging
The spin echo pulse sequence is a versatile sequence which uses a 90° excitatory
RF pulse followed by at least one 180° pulse. This sequence can be used to produce spin
density, T1-, and T2-weighted images. The main characteristic of the spin echo is the 180°
“refocusing” pulse. This pulse results in rephasing of the transverse relaxation components
into an “echo” allowing for more signal acquisition. For a conventional spin echo sequence
at 1.5T, typical parameters for T1-weighted images are TE=20ms and TR=500ms. Typical
parameters for T2-weighted images are TE=80ms and TR=2000ms [59].
Fast spin echo (FSE) imaging improves on the conventional spin echo sequence by
reducing scan time. This is done by repeating the 180° refocusing pulse with signal
acquisition following each inversion, allowing for multiple readouts to be obtained within
one TR. The echo train length (ETL) parameter describes how many echoes are to be
acquired in one TR, with imaging time inversely proportional to ETL. The rapid imaging
achievable by FSE and the ability to produce many different image weightings make FSE
one of the most useful MR pulse sequences [62].

1.5.7 Introduction to RF technology
The main tool for MR imaging is the RF coil. These coils are the source of the
excitatory RF energy as well as the tool for receiving the MR signal. Transmit (Tx) coils
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are designed to generate a uniform oscillating electromagnetic field. Most often, this is the
RF coil incorporated within the MRI bore known as the body coil. To transmit RF energy
to excite a particular nucleus, Tx coils must produce an electromagnetic field that oscillates
at or near 𝜔0 for that nucleus. Additionally, the field must oscillate in a plane perpendicular
to the main field of the magnet to facilitate excitation of ⃑⃑⃑⃑⃑
𝑀0 . The amount of RF energy
required to excite a particular nucleus is determined through the transmit gain (TG). This
parameter determines how much energy is needed to induce a 90° flip angle and is used to
calibrate all other flip angles specified. Values for TG can depend on the subject imaged,
coil type, and sequence used. Often, the excitatory RF pulse is transmitted by one coil, and
the resultant MR signal is received by another coil. This allows for simpler RF coil designs
and when used together with transmission by the body coil of the MRI, allows for more
uniform excitation over the entire volume. However, it is also possible for a single coil to
serve both the Tx and receive (Rx) functions. This type of coil can reduce whole body
exposure to RF induced heating, allows for acquisition of more slices, and reduces artefacts
from tissues outside the volume of interest. Challenges that face Tx/Rx coils are the more
complex coil designs required, and reduced B1 field uniformity over the volume of interest
[62, 64].
The resonant frequency of the RF coil depends on the inductance (L) and
capacitance (C) of the components in the circuit. This is the frequency where the coil works
most efficiently for RF transmission and/or reception. Typically, the resonant frequency of
the coil can be tuned by adjusting capacitors placed along the conducting loop. Tuning
ensures that the coil efficiently responds to signal over a very specific frequency range.
The simplest Rx coil consists solely of a loop of copper wire tuned to the Larmor frequency
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of the nucleus of interest at a specific field strength. As seen in equation 1.1, 𝜔0 depends
on the main field of the magnet, meaning a hydrogen proton in a 3T system precesses at a
different frequency from a hydrogen proton in a 1.5T system or any other MR-visible
nucleus at the same field strength [58, 62].
Coils are available in a variety of geometries which can serve different imaging
needs. The most common are birdcage coils, surface coils, and solenoids. Birdcage coils
and surface coils will be discussed in greater detail. Of these geometries, the birdcage coils
are perhaps the most ubiquitous owing to their versatility and reliability. This coil geometry
can be used for Tx/Rx and creates a uniform excitation and SNR within its bore, making it
very useful for 3D imaging. The surface coil has the simplest geometry and can often exist
as a simple loop. This type of coil can be used to interrogate very specific regions of the
body, and as this coil is able to be shaped to the region of interest, an SNR increase can be
observed as noise from outside of the sampled area is filtered [64]. However, this comes at
the cost of imaging volume and signal falls off as distance from the surface of the coil
increases. Surface coils perform best when the coil size is close to the size of the imaged
object. Unfortunately, its 2D geometry results in a non-uniform receive profile. Images
produced from a surface coil tend to have high SNR near the coil surface with rapid signal
fall off as distance from the coil increases. Correction pipelines are often used to correct
for non-uniformity in images from surface coils [65]. Surface coils can be arranged into an
array, which extends the volume of useable SNR of a single small surface coil. This allows
for imaging with a surface coil with high sensitivity over a larger volume [62].
There are additional challenges faced by surface coils with Tx/Rx capabilities.
When setting TG in surface coils, the spatial inhomogeneity of the emitted RF energy
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presents a major challenge. Due to the asymmetry of excitation, as RF energy increases,
the region in the coil where nuclei are flipped 90° shifts throughout the sample volume.
This can be ameliorated with a reference marker and shift reagent. A shift reagent is a
molecule which can affect the magnetic field experienced by certain nuclei, and thereby
shift the precession frequency of that nucleus. The amount of frequency shift the nuclei
experiences depends on the reagent and its concentration in the solution with the nuclei of
interest. Frequency shifts to the tune of a thousand Hz are possible [66]. When an RF coil
tuned to a specific nucleus is used on a subject and a shift reagent solution, two MR signal
peaks will be detected. One peak will belong to the 𝜔0 of the nuclei within the subject,
while the other peak results from the impact of the shift reagent. If this shifted peak is
distinct and well resolved from the subject peak, it can be used as a reference for setting
the RF energy input into the system. By placing the shift reagent solution in a known and
consistent position, RF energy input can be evaluated for this reference point across
multiple imaging sessions. When used in conjunction with a surface coil, reproducible
excitation profiles can be generated [64, 66].
Despite different coil geometries, MR signal is usually received in the same way.
After excitation, the resulting precessing transverse magnetization induces a voltage in the
RF coil. This voltage oscillates at the Larmor frequency with an amplitude that decays
exponentially with a time constant given by T2*. It is this voltage signal that is amplified
by the receive channel and passed on to a computer for processing into an MR image [62].
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1.6 Sodium magnetic resonance imaging
As discussed previously in section 1.2, tissue sodium levels are significantly
impacted in cancer and other diseases. Sodium is one of the two endogenous nuclei suitable
for human MRI [21]. Changes in total tissue sodium concentration (TSC) as measured by
sodium MRI (23Na MRI ) are more sensitive to disease changes on the molecular level in
conditions like cancer, stroke, or multiple sclerosis compared to proton MRI [67]. This
section will provide background on the techniques and challenges associated with imaging
sodium using MRI.

1.6.1 Sodium MRI
Nuclei suitable for MRI require a magnetic dipole moment formed from a non-zero
3

spin value. Sodium fulfills this requirement as all sodium nuclei have a nuclear spin of 2,
allowing it to present a detectable MR signal. However, the nature of the sodium nucleus
presents challenges specific to its nuclear characteristics. Magnetic resonance signals also
depend on 𝛾̅ and the in vivo concentration of a nucleus. The signal in MRI is approximately
proportional to 𝛾 3 . Given that the 𝛾̅ of sodium is only 11.262MHz T-1 compared to
42.577MHz T-1 for 1H, the available sodium signal is significantly less than the available
proton signal. Additionally, the average in vivo TSC between the intra- and extracellular
environments is approximately 40mM [67]. Comparatively, the average concentration of
water-associated protons is 80M. Combined, these factors make the sodium signal much
smaller and more difficult to detect compared to proton (~30,000 times lower) [14].
However, nearly 100% of sodium in vivo exists as the MR sensitive isotope, meaning most
of the biologically available sodium contributes to the detected sodium signal [13].
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Additionally, the

3
2

nuclear spin has implications for the behaviour of the sodium

signal. In addition to a magnetic dipole moment, sodium has an electric quadrupolar
moment that interacts strongly with the electric field gradients in its environment. In
addition to dipole interactions, these quadrupolar interactions cause the sodium nucleus to
exhibit biexponential T2 relaxation. The T2 relaxation of sodium has a slow component
(T2,slow ~15–30ms) and a fast component (T2,fast ~1–5ms) owing to its biexponential nature.
The T1 relaxation of sodium is mono-exponential but is also rapid at ~30-40ms [14]. The
range of these relaxation values also depends on the tissue of interest. Within the brain,
white matter and grey matter have relaxation times that differ from cerebral spinal fluid
(CSF) [13]. These relaxation values are listed in Table 1-2.

Table 1-2. Sodium relaxation times for human brain tissues in vivo. These ranges are based
on references [13, 68, 69] and references within.
To maximize acquired sodium signal, 23Na MRI requires specialized hardware and
software. Custom RF coils tuned to the 𝜔0 of sodium and an MR system fitted with
broadband transcieve capabilities are required to image sodium. In addition, sequences for
sodium require ultrashort echo times (UTE) less than 0.5ms. These sequences also typically
acquire at low resolutions with short excitation RF pulses to minimize sodium signal loss
and maximize SNR [70]. Overall, sodium imaging sequences require longer acquisition
times and more averages to obtain high SNR. However, there are technical limits regarding
how long a subject can be imaged due to subject motion and equipment stability. Therefore,
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efficient sequence design is necessary for clinical applications. Details regarding 23Na MRI
sequences will be expanded in the following section.

1.6.2 Sodium imaging sequences
Sodium imaging sequences prioritize maximizing SNR to overcome the inherent
limitations of imaging sodium in vivo. MR sequences designed with UTE in mind aim to
avoid the short T2 effects associated with the sodium nucleus and allows for quantitative
23

Na MRI [21]. Ideally, this TE needs to be shorter than 0.5ms to detect both T2 components

of sodium [13]. One of the methods used to minimize TE is the adoption of a radial k-space
encoding scheme rather than Cartesian. In Cartesian k-space encoding, a phase encoding
gradient and frequency encoding gradient are required, which in essence allow the MR
signal to be read out across the plane line by line. However, there is no signal acquisition
during the time needed for the phase encoding gradient – resulting in undesirable losses in
SNR when imaging sodium.
Sodium imaging sequences like 3D projection reconstruction (3DPR) and twisted
projection imaging (TPI) use a radial encoding scheme. These methods apply a short, hard
excitation pulse, followed by radial gradient trajectories to acquire from angular
projections (3DPR) or spiraled trajectories (TPI). The 3D encoding gradient eliminates the
need for phase encoding gradients as the MR signals can be read outwards from a central
point. These sequences are able to shorten TE significantly compared to phase encoded
sequences [21]. A traditional 3DPR imaging scheme relies on these constant radial
projections to fill in k-space. However, it’s limited by over-sampling in the central regions
of k-space (low-spatial frequency) and under-sampling in the edge regions of k-space
(high-spatial frequency) which can result in blurring [21, 71]. The TPI imaging scheme
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overcomes this limitation of 3DPR. Rather than reading the MR signal out in straight lines
from center out, the readouts for this scheme follow varied spiral like trajectories to
uniformly sample k-space producing high SNR images. However, TPI is limited by its
complex implementation and high hardware demands [21, 70].
A different imaging scheme that is based on 3DPR is the density-adapted 3DPR
(DA3DPR) sequence. This sequence can match the SNR efficacy of TPI without the
hardware demands. The main improvement DA3DPR makes on traditional 3DPR imaging
is overcoming the non-uniform k-space sampling. Ultimately this sequence requires many
trajectories to fully cover all of k-space to satisfy the Nyquist sampling criterion. Overall
DA3DPR imaging has been demonstrated to acquire images with increased SNR and
reduced blurring [72].

1.6.3 Tissue sodium concentration
There are different ways to interpret the sodium MR signal, with considerations for
each. The sodium signal can be measured quantitatively, either as TSC or the intracellular
sodium concentration, given as an absolute sodium concentration measurement in mM
[21]. The intracellular concentration is of particular interest because of its sensitivity to cell
viability and ion homeostasis, which are implicated in disease states in neurodegenerative
diseases [14]. TSC is a weighted average of the intracellular and extracellular sodium
compartments [67]. This is different from obtaining measurements of the intracellular
sodium concentration specifically. Isolating sodium compartments requires significant
post-processing of the images and multiple image acquisitions [14].
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It is also possible to quantify the sodium signal by looking at changes in the signal
intensity. However, this method has some limitations owning to possible differences
between acquisitions as signals can be confounded by non-uniform spatial distributions of
the flip angle (𝛼). Therefore, maintaining the same spatial distribution of 𝛼 between scans
is important for accurate measurements [21]. Ultimately these methods of sodium
quantification are possible as they are based on spin-density weighted imaging, made
possible by sodium sequence designs.

1.7 Project aims and hypothesis
The aim of this thesis was to conduct a preliminary study investigating treatment
effects using sodium MRI. A DA3DPR sodium imaging sequence was implemented for
quantitative small animal imaging at 3T and

23

Na MRI for examining longitudinal

treatment response in pre-clinical models of GBM was investigated. Implementation and
optimization of the DA3DPR sequence for quantitative small animal sodium imaging was
evaluated using a curved butterfly surface coil. The optimized sequence and imaging
protocol were used to evaluate longitudinal changes in TSC in a preclinical rat model of
GBM. Proton (T2, pre- and post-contrast T1) and sodium images were acquired and coregistered to evaluate changes in tumour growth and total tissue sodium concentration over
time.
It was hypothesized based on the biological relevance of sodium in tumour biology,
that significant changes in TSC would be observed in response to treatment with TMZ.
Treatment with TMZ can affect sodium levels in tumours through cell death – which can
either result in decreased sodium levels due to a reduction in the Warburg effect, or
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increased sodium levels due to increases in the extracellular volume fraction [20, 73].
Specifically, it was hypothesized that TSC in the tumour region would decrease with
treatment due to the decrease in metabolism. It is important to recognize that the DA3DPR
sequence used for this imaging is only sensitive to total TSC and cannot differentiate
between intracellular and extracellular compartments. Therefore, the expected changes
would be dependent on the combined changes of sodium concentration within the cells and
in the surrounding extracellular space.
The goal of this work was to investigate the potential for sodium as an MR
biomarker for tumour response that could be more specific than current clinical criteria.
This could potentially improve on the challenges faced when imaging GBM and the impact
these challenges have on treatment and patient response.

1.7.1 Challenges of COVID-19
Over the last 16 months, we have been faced with unprecedent challenges in the
form of the COVID-19 global pandemic which greatly impacted our ability to conduct preclinical research. In addition to delays caused by research shutdowns, many new obstacles
with regards to accessing resources and personnel needed for experimental procedures
arose after we recovered from the first wave. From new scheduling systems for space
access to difficulties booking training sessions¸ many factors contributed to challenging
progress. This thesis was ultimately able to be brought to fruition with the support of the
Animal Care and Veterinary Services team in the middle of the pandemic. Additionally,
support provided by fellow lab members, my supervisor, as well as the university helped
to overcome the challenges and limitations imposed on us by the pandemic.
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Chapter 2
2

Materials and methodology

2.1 RF Hardware
To facilitate co-registered proton and sodium imaging, two separate radiofrequency
(RF) coils were utilized: a proton birdcage RF coil and a curved sodium surface coil. The
RF coils were designed such that the curvature of the sodium surface coil could fit snugly
within the bore of the larger cylindrical proton birdcage coil. This would allow for coregistered images to be acquired and for the coils to be moved relative to each other.
Proton imaging was conducted using a custom-built 8-rung birdcage coil and RF
shield. The dimensions of the cylindrical acrylic tube for the coil was 88.9mm in outer
diameter (OD) with a form thickness of 3.2mm and 264mm in length. This tube had two
outer nylon rings used to locate an RF shield concentrically about the RF coil. The
dimensions of the shield were 356mm long with an 165mm OD. The loaded resonant
frequency of this coil was tuned to 127.74MHz, the Larmor frequency of water protons at
3T. The Q factor for the birdcage coil was 200 [1]. The sodium images were obtained
using a custom-built rectangular butterfly surface RF coil constructed on a cylindrical
former with a diameter of 55.65mm. The dimensions of each surface coil were 47.86mm
by 78.92mm and the coils were overlapped by approximately 15.66mm. Both channels on
the coil were tuned to 33.8MHz while loaded with a 1% agarose phantom with a sodium
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concentration of 50mM filling the entire coil imaging volume. Figure 2-1 shows the image
of the sodium coiled used.

Figure 2-1. Sodium surface coil shown from (L) a top-down view and (R) down the
vertical axis with a cylindrical 50mM 1% agarose phantom placed in the coil.

2.2 Imaging phantoms
Custom imaging phantoms were constructed to evaluate the performance of the
sodium RF hardware, imaging sequence, and intensity correction pipeline. Cylindrical 1%
agarose phantoms were produced that matched the curved form of the surface coil. This
method allowed for the phantom to completely mold to the shape of the coil and fill the
entire imaging region. The phantoms were chosen to have a sodium concentration of
50mM, based on average physiological sodium concentrations [2].

2.3 DA3DPR protocol optimization for sodium MRI
Sequence evaluation and imaging was performed on a GE Discovery MR 750 3.0T
MRI (General Electric Healthcare, Milwaukee, WI, USA) [3]. The DA3DPR sequence was
provided by Dr. Akbari as described in Nagel et al. [4]. Sodium imaging was evaluated
with two coil configurations: imaging with sodium coil alone and imaging while the proton
birdcage was placed around the sodium coil. Imaging was performed at 1mm and 3mm
isotropic resolution for evaluation of the imaging SNR. Imaging at 1mm resolution was
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performed with the addition of an insertable gradient coil. Since excitation and encoding
gradients were activated at the same time, greater accuracy is required, especially
considering the radial encoding scheme which is more sensitive to imperfect gradients than
Cartesian schemes [5]. Accuracy was hindered by eddy current issues which resulted in
artifacts. Additionally, it was observed that 1mm voxels did not produce enough SNR to
obtain measurable TSC in tissue in a reasonable amount of time. To achieve useful imaging
SNR within a reasonable imaging session, it was evident that 1mm isotropic resolution
would be challenging, and 3mm isotropic resolution was chosen for the in vivo
measurements of tissue sodium concentration (TSC).
Imaging protocols at 3mm isotropic resolution were optimized with the addition of
a “shift agent”, thulium-1,4,7,10-tetraazacyclododecane 1,4,7,10-tetrakis(methylene
phosphonate) (Tm-DOTP5-) to a sodium reference vial [6]. The purpose of doping a
phantom with a shift reagent is to change the resonant frequency of the
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Na nucleus in

contact with the reagent. This “frequency-shifted” reference vial was used as a reference
marker in a known and consistent location across longitudinal imaging sessions. This
produced a well resolved second signal peak from the sodium inside the tube. This peak
could be used to determine the amount of RF energy needed to excite the magnetization of
the sodium nuclei through 90° at a repeatable position with respect to the RF coil. The
sodium peak from the imaging subject itself could not be used as within the imaging space
of the surface coil, increases in TG could alter the distribution of 𝛼 within the space. This
would be inconsistent between subjects and it would be difficult to reliably reproduce the
same excitation profile across different imaging sessions. Data reported by Winter et al.
was used to map the relationship between shift agent concentration and frequency shift for
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the sodium nucleus. In conjunction with tests using solutions of different concentrations, a
shift of 1000Hz was achieved given the solubility limits of Tm-DOTP5-. A solution of
200mM of Tm-DOTP5- and 2M NaCl solution was used as a reference peak for setting
transmit gain (TG) for the surface coil. By implementing the reference marker in a single
repeatable location for all longitudinal imaging sessions, a consistent and replicable
excitation profile can be achieved with a surface coil. The shift reagent reference tube
(75.85mm length by 11.42mm diameter) was placed in a defined position at the center of
the imaging region of the coil. The shifted peak was confirmed visually on the scanner and
TG was determined from the maximum observed amplitude of the shifted peak. This
reference tube was then removed prior to beginning sodium image acquisition.

2.4 Cell culture
C6 rat glioma cells (CCL-107, American Type Culture Collection, Manassas, VA,
USA) were cultured in Dulbecco’s Modified Eagle Media (DMEM) (Wisent, Montreal,
QC, CA) containing 10% fetal bovine serum (FBS), 1% antibiotic-antimycotic and
supplemented with 4-times concentration of non-essential amino acids and 2% Lglutamine. Cells were grown at 37°C in 5% CO2. Cells were evaluated for mycoplasma
using the MycoAlert Mycoplasma Detection Kit (Lonza, Basel, Switzerland).

2.5 Animal model
An orthotopic glioma model was used for this study. On day 0, 200-250g male
Wistar rats (Charles River Laboratories, Wilmington, MA, USA) underwent stereotactic
surgery for cell implantation into the brain. Fur on the superior side of the rat head was
removed and a midline incision was made. Fascia was pushed aside to expose the skull
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surface and bregma and lambda were landmarked and horizontally leveled. A 2.5mm burr
hole was drilled 1mm posterior and 3mm right-lateral to bregma. A 25G Hamilton
microliter syringe (Hamilton 700 series) was advanced to a 4mm depth and used to inject
106 C6 glioma suspended in 10L of phosphate buffered solution (PBS) at a rate of
3L/min. The needle was left in place for 1 minute before extraction. The surgical site was
flushed with a sterile saline solution to wash away any cells which may have effused from
the injection site through the burr hole. Finally, bone wax was used to fill the burr hole to
block any additional cells from effusing. Animals were imaged on days 7, 10, 12 and
imaged every 3rd day after that except for rat 1. This animal received imaging on days 7,
10, and then every 2nd day after that. When tumours reached a volume of greater than
150mm3, animals were designated to: first a control group which received no therapy (n=4)
and followed by a treatment group (n=3). The treatment group received 40mg/kg of
Temozolomide (TMZ, Sigma Aldrich, Miamisburg OH, USA) dissolved in dimethyl
sulfoxide (DMSO, Sigma Aldrich, Miamisburg OH, USA) via intra-peritoneal injection
for 5 consecutive days. At endpoint, animals were perfused, and tissue was collected for
histological examination. All animal procedures were conducted in accordance with
relevant guidelines by the University Council on Animal Care and the Animal Use
Subcommittee (AUP 2018-164).

2.6 In vivo imaging
2.6.1 Sodium imaging
Animals first underwent imaging with the sodium surface RF coil which allowed
for easier animal placement and adjustment. This was followed by subsequent imaging
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with the proton birdcage RF coil. The sodium coil was positioned on an MR compatible
tray comprised of a curved cylindrical acrylic former suspended from plastic rails. This
configuration placed the animal head near the isocentre of the MRI bore as well as allowed
for the placement of a proton birdcage RF coil and shield around the animal without any
additional repositioning of the animal (Figure 2-2). Solutions with sodium concentrations
of 30mM, 50mM, 70mM, and 100mM in 2mL reagent bottles were placed along the
underside of the coil. These reference vials were used for the correction of the RF coils
sensitivity profile and to determine absolute TSC.

Figure 2-2. An illustrative schematic showing the positioning of the proton birdcage,
sodium surface coil and animal position down the vertical axis. The proton birdcage is
attached to external rails which allow it to move independently from the sodium surface
coil.
All animal imaging was conducted on a GE Discovery MR 750 3.0T MRI (General
Electric Healthcare, Milwaukee, WI, USA). A detailed image showing the imaging setup
is shown in Figure 2-3. Sodium imaging was conducted using a density-adapted 3dimensional projection reconstruction sequence (DA3DPR) (TE=0.5ms, TR=100ms,
Taq=8ms, flip angle (𝛼)=90°, FOV=80mm isotropic, NEX=10, imaging time=12mins) [1].
The transmit gain for imaging was set based on a vial of 200mM Dm-DOTP5- and 2M
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sodium chloride solution placed in the center of the coil’s imaging area. This solution
produced a sodium signal peak with a shifted frequency of approximately 1000Hz [2].
Images were reconstructed using a custom MATLAB script (MathWorks, Natick, MA,
USA) to an imaging matrix size of 27 × 27 × 512 with 3mm isotropic imaging voxels.

Figure 2-3. A photograph showing a typical set up for sodium imaging. The sodium
coil and animal in supine position are placed on a specially constructed tray which
suspends an acrylic half-pipe between the rails. Anesthesia and heating can be placed
around the animal. The halfpipe is slid through the bore of the proton coil which is
centered by nylon end-rings to position it along the rails. This allows the proton coil to
be positioned central to the animal and sodium coil.

2.6.2 Proton imaging
To acquire proton images, the proton birdcage coil and shield were slid onto the
rails and positioned to be concentric with and centred on the sodium coil. For each imaging
session 3D T2-weighted images and 3D pre- and post- gadolinium-DTPA (0.5mmol/kg;
Magnevist, Bayer, Leverkusen, Germany) contrast enhanced (CE) T1-weighted images
were acquired. The T2-weighted images were obtained using a 3D fast spin echo sequence
(FSE) (CUBE, General Electric Healthcare, Milwaukee, WI, USA) with the following
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parameters: FOV=60mm isotropic, acquisition matrix=128×128, slice thickness=0.5mm,
bandwidth=62.50MHz, NEX=3, TR=2432ms, TE=60ms, echo train length (ETL)=120,
imaging time=12 minutes. The T1-weighted images were also obtained using a general 3D
FSE sequence with the following parameters: FOV=60mm isotropic, acquisition
matrix=128 × 128, slice thickness=0.5mm, bandwidth=31.25MHz, NEX=1, TR=281ms,
TE=18.2ms, ETL=10, imaging time=10 minutes. Post-CE images were acquired 30s after
Magnevist (Bayer, Leverkusen, Germany) injection.

2.7 Image processing
2.7.1 Intensity correction and quantification
Sodium images were reconstructed using MATLAB (MathWorks, Natick. MA,
USA), GE Orchestra (General Electric Healthcare, Milwaukee, WI, USA) and the
Michigan Image Reconstruction Toolbox (Jeffery A. Fessler, “Michigan Reconstruction
Toolbox”, web.eecs.umich.edu/~fessler/code/). Sodium images were reconstructed into an
imaging matrix volume of 27 × 27 × 512 with 3mm isotropic imaging voxels. To prepare
images for intensity correction, ITK-SNAP (www.itksnap.org, [7]) was used to perform
region of interest (ROI) segmentations. The subject and sodium reference vials were
segmented from the background noise using ITK-SNAP’s built-in semi-automatic
segmentation tool. The mask generated from this segmentation was used with a custom
MATLAB script (MathWorks, Natick. MA, USA) for purposes of correction of the nonuniform signal sensitivity profile of the sodium surface coil.
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Figure 2-4. Schematic showing the major steps and outputs in intensity correction
pipeline. 1) An intensity normalized sensitivity axial image of a 50mM 1% agarose
cylindrical phantom with four 50mM reference vials along the bottom. Acquired with
30 averages 2) A segmented and intensity corrected image of a 50mM 1% agarose
phantom with 30mM, 50mM, 70mM, and 100mM reference vials along the bottom. 3)
A linear regression formed through a plot of known sodium concentration in the
segmented reference vials versus the average signal intensity in the segmented reference
vials. The line is used to remap signal intensities in the image to their corresponding
concentration. Error bars represent standard deviation of pixel measurements in each
reference vial. 4) Final image and reported average concentrations ± SD after intensity
remapping showing the 50mM phantom and reference vials along the bottom.
Measurements in small ROIs range from 47.9 ± 2.7mM to 51.5 ± 1.6mM. The average
± SD across all 6 sample ROIs was 49.5 ± 2.5mM. 5) Showing the ROI selection (blue)
within the volume of the phantom (red) rendered from segmentations take in ITK-SNAP.
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To correct for intensity variation over the imaging area of the surface coil, a high SNR
image containing only sodium intensity variation was obtained by using a 50mM 1%
agarose phantom and 50mM reference vials. This sensitivity map was normalized to then
obtain a normalized sensitivity map which could be used to scale intensities in an in vivo
image. To process an in vivo image, a mask of the areas of interest (main area to be
corrected and reference vials) was made using the semi-automatic segmentation tool in
ITK-SNAP. This mask was eroded to address observable partial volume effects (PVE),
especially in the edge regions of the reference vials. The average noise in the image was
calculated from an averaged background ROI and then subtracted from each pixel to
address the offset across the imaging volume which improves the precision of the
quantification. Sensitivity correction was obtained by dividing the subject image by the
normalized sensitivity map which adjusts pixel intensities to account for the signal fall off.
Using the normalized sensitivity map, areas close to the surface of the coil are typically
divided by larger numbers while areas further away from the surface of the coil would be
divided by smaller numbers. This would offset the intensity fall of due to the surface coil.
To quantify sodium measurements from the intensity corrected image, first the
average intensities from the known reference vials were extracted. These intensity values
were mapped against their known concentrations to determine a line of best fit. This line
was used to remap the pixel intensities across the rest of the image to concentration values.
This pipeline was validated through the quantification of known 40mM and 80mM saline
phantoms which were used to fill the imaging volume. This was followed by in vivo
validation by evaluating healthy brain TSC in rats and comparing these values against
known values from literature. Healthy rats (n=3) underwent a proton and sodium imaging

51
session. Images were processed as described in section 2.6.2 and whole brain
segmentations were obtained to determine the TSC of the healthy brain.

2.7.2 Image analysis
Manual registration of sodium and proton images was achieved using rigid linear
transforms in 3D Slicer (www.slicer.org, [8]). Additionally, sodium images were
resampled into the same voxel spacing as the proton images. Measurements for tumour
volume from T1- and T2-weighted images were obtained from manual segmentations in
ITK-SNAP (www.itksnap.org, [7]). Tumour boundaries from T1-weighted images were
determined based on post-CE images. T2-weighted anatomical proton images were used as
a guide to manually segment the tumorous regions to determine tumour TSC values from
sodium images for each animal in the experiment.
As a comparison, matched baseline “contralateral” sodium measurements for each
animal, a tumour free region in the posterior portion of the brain – far away from where
the main tumour would grow was segmented out for measurement. Additional TSC
measurements from healthy, tumour-free animals were obtained using the same
registration methods. Whole brain segmentations were used to determine average healthy
brain TSC.

2.8 Endpoint histology
At experimental endpoint, animals were euthanized and perfused with 4%
paraformaldehyde (PFA) in PBS. The whole brain was then extracted and stored in 4%
PFA at 4°C for 24 hours. After fixation, brains could be placed in PBS at 4°C for long term
storage or prepared for cryo-sectioning.
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For cryo-sectioning, brains were placed in solutions of increasing sucrose
concentration (10%, 20%, 30%) until fully sunken to extract water content. After which
the brain would be embedded in optimal cutting temperature (OCT) medium and frozen on
dry ice before moving to long term storage at -20°C. Ten-micron sections were obtained
using a microtome-cryostat (Leica CM1860, Wetzlar, Germany) and stained for
hematoxylin and eosin (H&E). Whole-mount sectioned slices were scanned using the
EVOS imaging system (M7000, ThermoFisher Scientific, Waltham, MA, USA).

2.8 Statistics and analysis
Statistical analyses were performed using GraphPad Prism v8 (GraphPad Software
Inc., California, USA). A two-way ANOVA and Tukey’s post hoc was performed to
investigate endpoint TSC. Exponential growth curve fitting was performed to model
tumour growth based on tumour volume measurements over time. This relationship was
then used to determine the tumour growth rates. Linear regressions were performed to
identify any trends in the between measures and Pearson correlation analyses were
performed to determine the strength of those trends.
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Chapter 3
3

Results and analysis

3.1 Results
To evaluate sequence performance and optimization, image quality from different
DA3DPR acquisition protocols were evaluated. Comparisons between 1mm isotropic and
3mm isotropic imaging resolutions showed that overall SNR was higher using the
insertable gradient system compared to the clinical gradient system. Qualitative
observation indicated that sodium MR image quality at 3mm imaging resolution was higher
than at 1mm imaging resolution, as expected. Sequence implementation using the
insertable gradient system introduced new artefacts and challenges regarding feasibility as
unwanted image artefacts such as blurring, and ringing were common. Additionally,
hardware limitations were encountered due to the sensitivity of the radial sequence to eddy
currents and gradient imperfections. As a result, in vivo imaging was acquired without the
gradient insert system.
To optimize the addition of the shift reagent Tm-DOTP5- for 3mm imaging
resolution in vivo at clinical settings, a simulation of shift reagent concentration to reported
frequency shift based on past literature was created. The final concentrations of 23Na and
TmDOTP5- were determined by considering the amount of sodium for a well-defined peak
and the solubility limits of TmDOTP5- in water. Figure 3-1A shows the final observed peak
which has been shifted approximately 1300 Hz from the main sodium peak. The
combination of the DA3DPR sequence and the shift reagent was used to image a 50mM
1% agarose phantom. It was determined within the imaging area of the coil, an average
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SNR of 14.9 could be achieved for images averaged 10 times (imaging time=12 minutes).
A representative axial slice of a cylindrical phantom filling the imaging volume is shown
in Figure 3-1B. It should be noted, an asymmetric signal profile was observed from the coil
upon image reconstruction. This asymmetry was not observable from the bench and is
likely to be the result of something further down the receive chain. This asymmetry did not
affect analysis as the intensity correction pipeline was able to offset the profile.

A

B

Figure 3-1. (A) 23Na FID spectrum showing the (L) shift reagent signal and (R) signal
from 50mM 1% agarose cylindrical phantom with frequency centered on shift reagent
peak. (B) Representative axial slice of a cylindrical 50mM 1% agarose phantom
showing SNR of coil in imaging region. Image was acquired with 10 averages over 12
minutes.
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Figure 3-2. (A) Single representative animal from the non-treatment group. Bottom
panel shows a zoomed in view of sodium images overlayed onto T2-proton weighted
images at longitudinal time points. Tumours are outlined by yellow boundaries. (B)
Graph of average tissue sodium concentration ± SD for representative animal for both
the tumorous region and contralateral brain region. (C) Side-by-side H&E histology,
T1-weighted image, and sodium image of non-treated animal at endpoint. Tumours are
outlined in yellow and the brain in brown.
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Figure 3-3. Graph of average tissue sodium concentration ± SD for (L) tumour and (R)
contralateral tumour-free region for all imaging time points. Top row shows all animals
and bottom row averages all cohorts to obtain a linear regression for all animals. Dotted
lines show the 95% confidence interval. The slope for TSC versus time for the combined
tumour group was significantly different from zero (p<0.05) and not significantly
different from zero for the combined contralateral brain group (p=0.15). Slopes for the
tumour region and the contralateral tumour-free region were significantly different
(p<0.05).
A total of 7 rodents were monitored using longitudinal sodium imaging at multiple
time points post-implantation. These animals were split into control (n=4) and treatment
(n=3) groups. Figure 3-2A shows a representative animal’s sodium, proton and overlaid
sodium and proton MR images while the animals’ representative TSC measurements over
time are show in Figure 3-2B. A visible increase in the area and concentration of TSC
localized to the tumour can be observed starting from day 12. T1-weighted proton images
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and sodium images are also shown next to a corresponding H&E histology slide in Figure
3-2C. This shows the correspondence between the histological tumour area and what can
be observed from the imaging data. The boundaries of the tumour are clearly visible and
well defined in the T1-weighted images, however the reduced resolution (3mm isotropic)
in the sodium images show a lack of similar definition. Figure 3-3 shows the longitudinal
changes in TSC across all animals in both control and treatment groups. Increasing TSC
over time can be observed in the tumours while TSC in the contralateral brain stays
relatively constant for both the control and treatment groups. The increase in TSC over
time in the tumour has a slope significant from zero (slope = 1.16 ± 0.21mM/day,
p<0.0001). The slope of TSC versus time in the contralateral brain regions is not
significantly different from zero (slope = 0.23 ± 0.16mM/day, p=0.15).
Contrast enhanced T1-weighted imaging was acquired for 5 animals out of the total
7. Animals in both treated (n=3) and non-treated (n=2) cohorts received CE MRI.
Although T1-weighted imaging is typically used in clinical imaging, our model saw the
volume measurements from the T2-weighted images better captured the bounds of the TSC
distribution. Overall, there was more inhomogeneity in T1-weighted images, which could
be indicative of necrosis or changes in the permeability of the blood tumour barrier.
Tumour morphology from T2-weighted images were found to better correlate with tissue
sodium distribution compared to T1-weighted images, especially in control animals. This
was qualitatively confirmed by visible inspection at endpoint by histology. The volume
difference between the T1-weighted and T2-weighted measurements was on average 350.4
± 123.18mm3 for control animals at endpoint. An example of this discrepancy can be seen
in Figure 3-4.

59

Figure 3-4. Representative animal showing a sagittal view of the brain (from left to
right: T1-weighted post-CE, T2-weighted, sodium MRI images). Outline shows the
boundaries of the tumour as taken from the T2 volume also overlayed on the same
position in the T1-weighted post-CE and sodium images. Image resolution for the above
images were 0.5mm3, 0.5mm3, and 3mm3 respectively.
Figure 3-5 shows the tumour volumes extracted from the T2-weighted proton
images plotted against the average TSC measurements from the tumours for both groups.
Average tumour TSC increased with volume for both non-treated and treated animals.
However, the rate of this increase did not differ significantly between groups (p=0.42). A
vertical line indicating a volume of 150mm3 is included as that is the volume where reliable
quantification of sodium signal localization to the tumour was possible. This represents
approximately six sodium imaging voxels for our TSC imaging. Overall, average tumour
volume at endpoint in the control group trended higher than in the treatment group,
however this difference was not significant.
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Figure 3-5 Graph of average tissue sodium concentration for (L) non-treated and (R)
treated for measured tumour volumes. Dotted lines show the 95% confidence interval
for the linear regression. Slopes of average TSC versus tumour volume were not
significantly different at a 95% confidence level for non-treated versus treated groups
(p=0.42).
Figure 3-6 shows tumour growth rate derived from volume measurements plotted
against average TSC. A positive correlation between growth rate and average tumour TSC
for both control (r=0.78) and treatment cohorts (r=0.67) was observed. The slope for this
relationship did not differ significantly between groups (p=0.57). The range of growth rates
observed in the control group is larger than the range of growth rates observed in the
treatment group. The maximum growth rate in the control group is 265.8±0.1mm3/day
while the maximum in the treatment group is 136.2±0.2mm3/day. This error was obtained
from the 95% confidence interval. The uncertainty in the difference of these two rates is
129.6±0.3mm3/day. As this difference is represents greater than 4 standard deviations, the
difference between the growth rates are significant.
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Figure 3-6. (A) Graph of average tissue sodium concentration in tumours for (L) nontreated and (R) treatment cohorts for tumour growth rate. Dotted lines show the 95%
confidence interval for the linear regression. Slopes not significantly different at a 95%
confidence level (p=0.57). (B) Graph of average doubling time of tumour volumes for
the non-treated and treated animal groups. Differences in doubling times were not
significant (p=0.23).
The relationship between time after injection and ΔTSC between the tumour and
contralateral brain showed that differences between brain region did not significantly differ
depending on cohort and overall trended in a positive direction. It was observed that overall
differences in TSC between the tumour region and contralateral brain increased. Lastly, a
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comparison of TSC at endpoint across treatment groups and brain regions showed that
differences were significantly different only between regions (p<0.001) and not between
cohorts.

Figure 3-7. Graph of ΔTSC between tumorous region and contralateral brain for time
matched points for (L) untreated and (R) treatment cohorts. Dotted lines show the 95%
confidence interval for the linear regression. Slopes are not significantly different at a

95% confidence level (p=0.18).
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Figure 3-8. Graph of average TSC ± SD at endpoint for the tumorous region and
contralateral brain region. Differences between brain region are significant for both nontreatment and treatment groups (p<0.0001). Average tumour TSC (p=0.59) and average

contralateral brain TSC (p=0.84) at endpoint were not significantly different between
treatment and non-treatment groups.
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3.2 Discussion
In this study we demonstrated the first implementation of DA3DPR sodium
imaging to study an orthotopic glioblastoma tumour model in rats at 3T. The sequence was
successfully implemented at 3T using the clinical gradient. In addition, sodium images
from the surface coil imaging was successfully quantified using our inhouse algorithm. The
implementation of this sequence with the addition of a proton birdcage which slid over the
sodium setup meant that anatomical images could be intrinsically co-registered with
sodium images. Our preliminary study showed that the imaging protocol was sensitive to
changes in TSC over time and in different brain regions. In the clinic, CE T1-weighted
imaging and T2-weighted imaging are typically used to assess glioma. A combination of
T1-weighted and T2-weighted proton anatomical images with sodium MRI images allowed
for the investigation of the relationship between TSC and the physical characteristics of the
tumours, such as volume and growth rate. Sodium MRI could additionally add molecular
information about glioma for this preclinical model.
The segmentation based on the anatomical images allowed for the extraction of
tumour volumes and TSC. Based on tumour volume measurements and observable signal
localization, sodium signal can be reliably quantified for tumour volumes larger than
150mm3. Tumour volume was a limiting factor in sodium quantification due to the voxel
size in the sodium scans, thus diffuse areas of the tumour or offshoots of the main mass
which can be visualized in the proton scans cannot be detected in the sodium. Voxel size
will likely continue to be a limiting factor in sodium MRI studies as most studies report an
isotropic resolution of around 2.5mm3 in both preclinical and clinical settings [1-4]. It
should be noted that imaging in these studies tended to have a greater number of averages
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and therefore longer imaging durations. The analysis showed that TSC increased over time
within the tumours as they grew. Increases in tumour growth rate were additionally
correlated with increasing TSC. Ultimately this indicates that the sodium imaging protocol
is supported by anatomical imaging as TSC was extracted based on the observable tumour
from T2-weighted images. Based on the co-registration and segmentation, changes in the
TSC could be observed specific to the tumour. This analysis revealed that this sodium
imaging method and animal model did not show differences in the tumour TSC between
control and treatment group animals. A few studies have investigated long-term trends in
pre-clinical models using sodium MRI and clinically relevant proton sequences, thus the
insights provided by this study provide valuable insight into possible trends and
considerations for further studies of this type [5].
An evaluation of growth rate determined from the longitudinal segmentations
showed there was an increase in tumour volume doubling time observed for animals in the
treatment cohort. This difference is not significant therefore it is difficult to say whether
treatment influenced the rate of growth of the tumours. This could explain the similarities
in the TSC values for both cohorts. It should be noted that the range of growth rates was
greater for control animals than the range of growth rates for treatment animals, which may
indicate treatment influenced tumour growth which was not reflected in the TSC. This
could partly be owed to the differing durations of survival between cohorts. The
chemotherapy regiment was aggressive and animals in the treatment cohort deteriorated
rapidly compared to animals in the control cohort. As a result, overall survival times for
the treatment cohort were shorter. Ultimately it is unclear if the lack of differences were
due to limitations with the imaging protocol itself, or limitations of the animal model.
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A key measurement evaluated was the time matched difference between TSC in the
tumour and TSC in the contralateral brain (ΔTSC). These differences increased over time
as we observed increases in the tumour TSC compared to the relative steadiness in the
contralateral brain TSC. It is important to recognize that the contralateral brain is not a
perfect measurement of baseline TSC to evaluate changes against. As it is in the same organ
as the tumour, this region is not healthy and is affected by the extracellular tumour
environment. Inflammation, infiltration, and extracellular environment changes are
potential factors that could affect the contralateral side [6]. These changes, in particular
inflammation would result in TSC increases which may explain the observed upwards
trend [7]. It is also likely that the chemotherapy had some effect on the cells in the
contralateral brain. TMZ is not a targeted therapy and specifically functions via DNA
alkylation, therefore all dividing cells in the body would be affected to some degree and
cell death is likely to increase in the healthy dividing glial cells in the brain [8]. Therefore,
the slight increase in TSC over time observed in the contralateral brain may point towards
a combination of these described factors. We are interested in the contralateral region
despite these limitations as it is within the same organ as the tumour and can therefore
present the most relevant point for comparison.
We incidentally observed that regions of high TSC better correlated with tumour
boundaries observed in T2-weighted images rather than T1-weighted images. This is of
particular interest as evaluating changes on T1-weighted images is the current clinical
standard for evaluating treatment response. More recent guidelines for evaluating treatment
response such as the Response Assessment in Neuro-Oncology (RANO) evaluate T2weighted images in addition T1-weighted images, however this guideline is still mostly
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used for clinical trial purposes [9]. This indicates that sodium images provide information
beyond that of T1-weighted proton imaging, and that T2-weighted contrast may be more
specific to tumour size.
While our limited imaging was ultimately not able to discern between treatment
and control groups, it is important to take into considerations the limitations and factors
which impact this conclusion. Optimizing the model to be more sensitive to treatment could
provide a way to better interrogate treatment effects on TSC changes. As mentioned
previously, animals which received treatment experienced a more rapid decline due to the
burden of chemotherapy in addition to the disease burden. This affected their overall
survival and it is possible that animals were sacrificed before sodium changes could appear.
Changing the timeline and method(s) of treatment for the animal model could potentially
improve on this study. In a previous study by our group the same animal model was
evaluated using magnetic resonance spectroscopic imaging of the metabolism of
hyperpolarized [1-13C] pyruvate. Animals were placed into one of 4 groups receiving: no
treatment, chemotherapy by TMZ, radiotherapy, and concurrent chemo-radiotherapy. It
was observed that animals which received the concomitant chemo-radiotherapy had longer
survival compared to administering each therapy individually or no therapy at all [10]. This
indicates that treatment influences survival and this effect can be modulated by the choice
of which treatment to prescribe. By extending the timeline and lessening the burden of
treatment, animals in the treatment cohort could survive for a greater length of time, which
could allow any effects due to treatment to be more clearly observable. A similar study
conducted at 9.4T evaluated animals over a much longer timeline after treatment [11]. In
this study 10,000 9L cells were implanted in Fischer rats. These cells were permitted to

68
grow for 17 days prior to a single treatment session with carmustine (BCNU). Animals
were monitored for up to 30 days after treatment began. Through this extended timeline,
an increase in TSC was observed until 5 days after treatment before a decrease was
observed. Our results show a similar initial trend with increasing TSC however we
ultimately were not able to follow the animals for an extended period after treatment. Given
the shorter treatment duration compared to our study, it would be expected these animals
received less therapeutic burden and that contributed to there improved survival.
The Warburg effect describes the altered cellular metabolism found in cancer cells.
The major characteristic of this altered metabolism is the increase in glycolytic activity
even in the presence of oxygen. This activity decreases the pH in the tumour
microenvironment due to an increase in proton concentration. The electro-chemical
exchange that occurs to rebalance the cell pH increases the local TSC inside the cancer
cells [12-14]. This will reflect in changes in the intracellular and extracellular environment
as the cells work to maintain electrochemical homeostasis. Ultimately our DA3DPR
imaging is only sensitive to total TSC and not to specific sodium compartments. This
dependence on the intracellular and extracellular compartment means that the observed
TSC can be affected by any changes that may occur in these spaces such as changes in the
extracellular sodium concentration and the relative volumes of these two compartments
[7].
It is also important to recognize the impact of PVE on this study. Due to the large
voxel size and reliance on segmentations based on anatomical proton images to obtain
tumour TSC measurements, there are important considerations regarding the impact of
PVE. Primarily, there is a consideration for the range and error associated with TSC. Many

69
segmented voxels may contain sodium measurements from areas both inside and outside
of the tumour. This ultimately impacts the accuracy and measurement uncertainty
associated with the sodium observations. This challenge is likely to persist in applications
involving sodium MR due to current the inherent spatial resolution associated with using
spherical k-space trajectories and the rapid signal relaxation [15].
Sodium MRI has applications as a clinical molecular imaging modality due to its
comparative ease of implementation compared to other molecular imaging techniques.
Currently most of the research into preclinical sodium MRI occurs at high field strengths
[11, 16]. While high field MR research has limited applicability to clinical translation,
studies at lower fields have been conducted on humans [3, 4, 17]. These studies tend to
focus on evaluating if TSC differences can be quantified for different disease states such
as multiple sclerosis, hypertension, and diabetes [18-20]. Experimental work for
interrogating specific applications and biomolecular relationships will still rely on
preclinical imaging.
In conclusion, this study has successfully implemented a quantifiable DA3DPR
imaging protocol for orthotopic C6 rat glioma and was able to characterize changes in the
tumour TSC over time and between brain regions. Relationships between tumour growth
rate and TSC was observed as well as better characterization of the relationship between
sodium signal and tumour morphology based on T1- and T2-weighted images. As this study
is a preliminary study, we saw no differences between the treated and non-treated groups.
Future work for this study will include improving the animal model to allow for a longer
experimental timeline as well as expanding the size of the groups for increased statistical
power. This will likely provide a greater period for any changes due to treatment to
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manifest and improve overall survival in the cohorts. As mentioned previously, our
research group has previously studied this model with animal cohorts which also
underwent radiotherapy and concurrent chemo-radiotherapy. Including these treatment
cohorts in a future sodium MR study would improve our understanding of how TSC can
be affected by different treatment methods. This could also provide insight into more
clinically relevant treatment responses as the standard of care for GBM includes concurrent
chemo-radiotherapy. Lastly, the ability to move birdcage coils independent of the sodium
coils introduces the opportunity to study the relationship sodium and proton imaging may
have with other molecular MR markers such as hyperpolarized

13

C-labelled metabolites.

This would provide additional molecular imaging metrics to observe the relationship
between metabolism and TSC.
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Chapter 4
4

Overview
This thesis highlights the opportunities and challenges associated with the use of

sodium MRI for assessment of pre-clinical tumours. An imaging protocol was optimized
for a pilot investigation of changes in sodium in a preclinical treatment model of
glioblastoma. Sodium levels were demonstrated to be sensitive to tumour growth in a C6
GBM rat model. However, the model itself presented challenges when investigating the
differences in TSC when treatment is applied. The main scientific contributions of this
work will be summarized below.

4.1 Summary and conclusions
For this thesis, a new imaging sequence for sodium was introduced to our facilities
and optimized for in vivo imaging using a surface coil. This protocol was then applied to
investigate the use of sodium MRI for evaluating a preclinical C6 GBM rat model. This
work began with overcoming the challenges associated with the implementation of the
DA3DPR sequence and understanding the limitations of what was achievable given our
equipment. This involved tuning and matching the sodium surface coil while loaded with
a phantom and examining the performance of the coil over repeated imaging experiments.
Ultimately, the protocol was optimized for imaging in clinical imaging mode at 3mm
isotropic resolution. The use of a shift reagent and reference vials allowed for repeatable
control of the RF transmit gain and correction of the non-uniform surface coil sensitivity
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profile. This permitted extraction of absolute measurements of the in vivo tissue sodium
concentration throughout the entire rat head.
Longitudinal animal imaging experiments evaluated changes in TSC over time
between a non-treated group (control) and a treatment group which received chemotherapy
in the form of TMZ. These experiments showed that TSC increased over time as it was
correlated with tumour growth. TSC within the tumour increased with both tumour volume
and growth rate. No differences were ultimately found between the non-treated group and
the treatment group when examining effects of treatment on TSC. Imaging was also able
to clearly differentiate between tumour TSC and TSC in the tumour free contralateral brain
region at endpoint. While TSC in the tumours was not significantly different between
groups there was a slight difference in doubling time in the treatment group compared to
the non-treatment group, with the treatment group having a slightly greater doubling time
although this difference was not significant.
In summary, this study demonstrated the feasibility of sodium MRI for pre-clinical
research. An imaging pipeline for sodium MRI and image processing was established and
longitudinal imaging was evaluated. This study showed that sodium MRI offers
complementary information to clinical MR scans typically used for evaluating GBM.
Sodium imaging was able to characterize some difference between CE T1-weighted images
and T2-weighted images and has potential to be sensitive to tumour growth. Overall, there
is potential for sodium MRI to be a useful molecular imaging biomarker for cancer in
addition to the current techniques for non-invasively monitoring tumours.
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4.1.1 Limitations
There were several limitations which affect the conclusions that can be drawn from
the results of this study. First it is important to note that there was no longitudinal histology
to validate changes observed in the proton or sodium MR. Histology for time matched
longitudinal points (at each imaging session) would have provided the gold standard
against which, imaging results could be validated. It’s important to note that the endpoint
histology presented here is most likely obtained when the tumour is the largest on the
imaging and therefore the most visible. Being able to more concretely correlate tumour
morphology to histology at earlier time points would have strengthened our understanding
of the reliability of sodium MR. However, to acquire this data would have required large
numbers of animals, been time-consuming, and costly.
The limited sample size (n=7) for this study made it difficult to draw firm
conclusions or differentiate if observed trends were significant. This is also significant
considering the large biological variation observed from individual animals with regards
to tumour progression. Increasing sample size would increase the statistical power for the
analyses and allow for concrete conclusions to be drawn regarding trends and patterns
observed within and between non-treatment and treatment groups.
The experimental timeline that we chose from a previous imaging study ultimately
resulted in difficulty observing treatment effects for this work. A high number of cells (106)
were initially injected into the animal and allowed to grow over time. This resulted in a
more rapid timeline for disease progression as well as more aggressive tumour growth. The
treatment regime was unable to successfully combat the tumour burden, and the effects of
chemotherapy additionally impacted animal health. Ultimately, we were unable to follow
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animals’ post-treatment to determine if treatment had any long-term effects on TSC. By
improving the experimental protocol/timeline and allowing for a slower disease
progression it is likely that post-treatment survival time could be increased, and treatment
effects might be more clearly observed. The effect of a prolonged timeline has been
observed in a slightly different model at higher field strengths. By decreasing the number
of cells initially injected and increasing the length of the experiment, they were able to
follow animals in the treatment cohort over the course of 45 days [1]. This is much longer
even compared to results from a hyperpolarized 13C imaging study which used this same
animal model and an expanded treatment regimen where survival was only observed to an
average of 18 days [2].
It is also important to recognize the limitations inherent to sodium MRI presented
by the hardware and the modality itself. The resolution for the sodium imaging was 3mm
isotropic at a field strength of 3T. It should be noted that this is similar to what other
researchers have achieved at this field strength for in vivo imaging. In the context of a rat
brain which is approximately 600mm3, this leaves an average of 200 pixels for the brain
[3]. This resolution limits the comparison we can draw between the anatomical references
and the sodium images as smaller areas in the higher resolution T1-weighted and T2weighted proton images will not be quantifiable in the sodium images. Quantification using
sodium imaging is additionally limited due to PVE due to the relative pixel to tumour size.
Taking into consideration regions of tumour visible on proton scans and not visible on
sodium due to voxel size differences, as well as voxels at the boarder of the tumour which
capture sodium signal both from tumorous and non-tumorous brain regions. Improvements
in sodium MR resolution would reduce the impact of PVE, however this may only be
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possible with more SNR-efficient sequences or imaging at higher field strengths. It should
be noted that increasing SNR at higher field strengths is ultimately limited in terms of
applicability as such applications cannot be replicated in humans and TSC in rodent and
other mammal tissues is similar to that in humans.

4.1.2 Future work
Future work for this study would include improvements to the pre-clinical model
which would allow animals to be evaluated over longer periods of time. This would
ultimately allow for the determination of any potential changes to TSC impacted by
treatment. Furthermore, the addition of treatment groups in addition to stand-alone
chemotherapy could lead to a more clinically relevant study. Current standard of care for
GBM includes concurrent chemo-radiotherapy. By including animal groups which receive
a combination of chemo-radiotherapy compared to those individual therapies could
improve our understanding of how TSC changes in response to different therapies. Further
work could include patient derived xenograft (PDX) models for GBM. As the cancer in
these models would be derived from patients, they are more likely to recapitulate the
biological behaviour of the tumours in humans and are more likely to respond to treatment
similar to clinical response [4-6].
The addition of other molecular imaging techniques to our imaging can
complement the information we learn from sodium MRI. Modalities such as PET or
magnetic resonance spectroscopic imaging (MRSI) of hyperpolarized 13C metabolites can
provide additional information specific to the metabolic characteristics of the tumour as
well as the environment within and surrounding the tumour [2]. The combination of
metabolic information gained from hyperpolarized

13

C MRSI within the tumour
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environment combined with information gained from sodium MRI would provide new
insight into understanding the relationship between these techniques as well as gaps
between the metabolic characteristics and the morphological characteristics proffered by
anatomical T1-weighted or T2-weighted imaging.

4.1.3 Significance and impact
It is important to recognize the challenges that GBM poses for disease management.
It is difficult to treat, requiring aggressive therapies and current clinical practices have not
evolved significantly in over a decade [7]. Improving diagnostic and quantitative
techniques provide new avenues for interrogating treatment response and tumour biology.
The development of sodium MRI and its improvements has applications for a variety of
diseases and conditions [8-10]. Sodium is the second most bio-available nucleus suitable
for MR imaging and provides information related to the biochemistry of the cells rather
than solely the morphology. By implementing the ability to obtain sodium and proton MR
images at 3T we demonstrate the potential this modality has for more applications at
clinical field strengths. In conclusion, this thesis provides a baseline for future longitudinal
animal studies looking to incorporate sodium MRI into studies of treatment response and
evaluating what information can be derived from multi-nuclear imaging at a more clinically
relevant field strength.
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Appendix B. – Sodium surface coil intensity correction
MATLAB script
Read Sensitivity Map
load nMap.mat
load mP.mat

Read Test Image
I = double(niftiread('RatSodium.nii.gz'));
IM=double(niftiread('RatSodium.mask.nii.gz'));

% Phantom
% Mask

%I = imgaussfilt(I, 20);
% Erode the mask (OPTIONAL)
se1=strel('disk',10);
se2=strel('disk',25);
%se=strel('sphere',2);
IM=imerode(IM,se1); % erode mask
% The final Mask is the AND function of the image mask and the sensitivity mask
Mask=IM.*mP;
MI=I.*Mask;

Display Test Image
figure(10)

% original image

montage(reshape(I,512,512,1,27))
caxis('auto')
colorbar
% Display final Mask
figure(11) % image of mask
montage(reshape(Mask,512,512,1,27))
caxis('auto')
colorbar
% Display masked image
figure(12) % eroded and multipled mask
montage(reshape(MI,512,512,1,27))
caxis('auto')
colorbar
% Display Sensitivity Map
figure(13) % sensitivity mask
montage(reshape(nMap,512,512,1,27))
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caxis('auto')
colorbar
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Obtain the noise level
%restrict to the first 18 slices
mask2 = Mask(:,:,1:18); % addressed the PSF by grabbing everything from slices that don't
contain vials
I2 = I(:,:,1:18);
Inv_Mask=1-mask2; % 0's where the object is, -1 everywhere else
Inv_Mask=imerode(Inv_Mask,se2); % erode into the noise space (big)
indx=find(Inv_Mask); % returns all non-zero indicies
noise_level=mean(I2(indx)); % uses those indices to find the mean noise from the original
image
std_noise=std(I2(indx)); % standard deviation of all the noise things
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Obtain Image with Sensitivity Compensation
%subtract offset from image
MI = MI - noise_level;
MI(MI<=0) = 0;
ISC=MI./nMap; %sensitivity compensation
ISC(isinf(ISC))=0;
ISC(ISC==0)=NaN;
figure(14)
montage(reshape(ISC,512,512,1,27))
caxis('auto')
colorbar

Obtain Regions
CC=bwconncomp(Mask);
% get the info from the image using the mask connected pixels
new_stats=regionprops3(CC,ISC,'Volume','VoxelIdxList','MaxIntensity','MeanIntensity','Min
Intensity','VoxelValues','Centroid','WeightedCentroid');
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figure(15)
colormap(gray)
imagesc(max(ISC,[],3))
hold on
for i=1:height(new_stats)
text(new_stats.Centroid(i,1),new_stats.Centroid(i,2),num2str(i),'Color','y')
end
title('Regions Identification')

Calibrate image to known concentrations
new_stats=regionprops3(CC,ISC,'Volume','VoxelIdxList','MaxIntensity','MeanIntensity','Min
Intensity','VoxelValues','Centroid','WeightedCentroid');
C=[30,50,70,100];
% Localize the vials
indx_c=find_conc;
% Obtain Mean and Standard Deviations for each object
stdev(1)=std(new_stats.VoxelValues{indx_c(1)});
stdev(2)=std(new_stats.VoxelValues{indx_c(2)});
stdev(3)=std(new_stats.VoxelValues{indx_c(3)});
stdev(4)=std(new_stats.VoxelValues{indx_c(4)});
%stdev(5)=std_noise;
x(1)=new_stats.MeanIntensity(indx_c(1));
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x(2)=new_stats.MeanIntensity(indx_c(2));
x(3)=new_stats.MeanIntensity(indx_c(3));
x(4)=new_stats.MeanIntensity(indx_c(4));
%x(5)=noise_level;
% Do linear fitting to obtain curve Signal Intensity vs. Concentration
mdl=fitlm(C(2:end),x(2:end));
% Slope
m=mdl.Coefficients.Estimate(2);
% Zero cross
b=mdl.Coefficients.Estimate(1);
% Obtain equation to get curve Concentration vs. Signal Intensity
% Slope
m2=1/m;
% Zero cross
b2=-b/m;
values = linspace(0,100);
% Display linear fitting
figure(16)
errorbar(C,x,stdev,'*k')
hold on
plot(values,m.*values+b,'-b')
hold off
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Obtain Concentration Map
C_Image=Mask.*(m2.*ISC+b2);
C_Image(C_Image<=0)=0;
C_Image(isnan(C_Image)) = 0;
figure(17)
montage(reshape(C_Image,512,512,1,27))
caxis('auto')
colorbar

Obtain Mean and Standard Deviation of Concentration Map
final_stats=regionprops3(CC,C_Image,'Volume','VoxelIdxList','MaxIntensity','MeanIntensity
','MinIntensity','VoxelValues','Centroid','WeightedCentroid');
figure(18)
imagesc(max(C_Image,[],3))
for i=1:height(final_stats)
stdev_c(i)=std(final_stats.VoxelValues{i});
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text(final_stats.Centroid(i,1),final_stats.Centroid(i,2),[num2str(final_stats.MeanIntensi
ty(i),4),'+/-',num2str(stdev_c(i),3)],'Color','w')
end
hold on
axis square
title('Regions Identification')

Validate fit from concentration map
Localize the vials
indx_c=find_conc;
% Obtain Mean and Standard Deviations for each object
stdev(1)=std(final_stats.VoxelValues{indx_c(1)});
stdev(2)=std(final_stats.VoxelValues{indx_c(2)});
stdev(3)=std(final_stats.VoxelValues{indx_c(3)});
stdev(4)=std(final_stats.VoxelValues{indx_c(4)});
%stdev(5)=std_noise;
x(1)=final_stats.MeanIntensity(indx_c(1));
x(2)=final_stats.MeanIntensity(indx_c(2));
x(3)=final_stats.MeanIntensity(indx_c(3));
x(4)=final_stats.MeanIntensity(indx_c(4));
%x(5)=noise_level;
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% Do linear fitting to oibtain curve Signal Intensity vs. Concentration
mdl2=fitlm(C,x);
% Slope
m3=mdl2.Coefficients.Estimate(2);
% Zero cross
b3=mdl2.Coefficients.Estimate(1);
values = linspace(0,100);
% Display linear fitting
figure(19)
errorbar(C,x,stdev,'*k')
hold on
plot(values,m3.*values+b3,'-b')
hold off

Function needed to match reference vials to correct concentration
function indx=find_conc;
figure(15) % Just to bring to the front the Region I.D. figure
d = dialog('Position',[300 300 250 150],'Name','Select One');
txt = uicontrol('Parent',d,'Style','text','Position',[20 110 210 40],...
'String','Select the correct index for each vial with the given concentrations');
txt.FontSize=12;
c1_txt=uicontrol('Parent',d,'Style','text','Position',[70 90 50 20],...
'String','30 mM','HorizontalAlignment','right');
c1_edit=uicontrol('Parent',d,'Style','edit','Position',[120 95 50
15],'Callback',@edit_c1);
c2_txt=uicontrol('Parent',d,'Style','text','Position',[70 75 50 20],...
'String','50 mM','HorizontalAlignment','right');
c2_edit=uicontrol('Parent',d,'Style','edit','Position',[120 80 50
15],'Callback',@edit_c2);
c3_txt=uicontrol('Parent',d,'Style','text','Position',[70 60 50 20],...
'String','70 mM','HorizontalAlignment','right');
c3_edit=uicontrol('Parent',d,'Style','edit','Position',[120 65 50
15],'Callback',@edit_c3);
c4_txt=uicontrol('Parent',d,'Style','text','Position',[70 45 50 20],...
'String','100 mM','HorizontalAlignment','right');
c4_edit=uicontrol('Parent',d,'Style','edit','Position',[120 50 50
15],'Callback',@edit_c4);
btn = uicontrol('Parent',d,...
'Position',[89 15 70 25],...
'String','Close',...
'Callback','delete(gcf)');
indx=[];
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function edit_c1(c1_edit,event)
indx(1)=str2num(c1_edit.String);
end
function edit_c2(c2_edit,event)
indx(2)=str2num(c2_edit.String);
end
function edit_c3(c3_edit,event)
indx(3)=str2num(c3_edit.String);
end
function edit_c4(c4_edit,event)
indx(4)=str2num(c4_edit.String);
end
% Wait for d to close before running to completion
uiwait(d);
end

Published with MATLAB® R2019b
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